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Abstract 
 
Type 2 diabetes mellitus is a metabolic disease characterised by defects in 
insulin secretion and insulin action and disturbances in carbohydrate, fat and 
protein metabolism.  Hepatic insulin resistance contributes to hyperglycemia 
and also leads to disturbances in fat metabolism in type 2 diabetes.  
Psammomys obesus is a unique polygenic animal model of type 2 diabetes and 
obesity, ideally suited for studies examining physiological and genetic aspects 
of these diseases.   
 
To identify metabolic abnormalities potentially contributing to the obesity and 
diabetes phenotype in P. obesus, indirect calorimetry was used to characterise 
whole body energy expenditure and substrate utilisation.  Lean-NGT, obese-
IGT and obese-diabetic animals were examined in fed and fasted states and 
following 14 days of dietary energy restriction.   
 
Energy expenditure and fat oxidation were elevated in the obese-IGT and 
obese-diabetic groups in proportion to body weight.  Glucose oxidation was 
not different between groups.  Obese-diabetic P. obesus displayed elevated 
nocturnal blood glucose levels and fat oxidation.  Following 14 days of dietary 
energy restriction, body weight was reduced and plasma insulin and blood 
glucose levels were normalised in all groups.  Glucose oxidation was reduced 
and fat oxidation was increased.  After 24 hours of fasting, plasma insulin and 
blood glucose levels were normalised in all groups.  Energy expenditure and 
glucose oxidation were greatly reduced and fat oxidation was increased.  
Following either dietary energy restriction or fasting, energy expenditure, 
glucose oxidation and fat oxidation were not different between groups of P. 
obesus.   
 
Energy expenditure and whole body substrate utilisation in P. obesus was 
similar to that seen in humans.  P. obesus responded normally to short term 
fasting and dietary energy restriction.  Elevated nocturnal fat oxidation rates 
and plasma glucose levels in obese-diabetic P. obesus may be an important 
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factor in the pathogenesis of obesity and type 2 diabetes in these animals.  
These studies have further validated P. obesus as an ideal animal model of 
type 2 diabetes and obesity.   
 
It was hypothesised that many genes in the liver of P. obesus involved in 
glucose and fat metabolism would be differentially expressed between lean-
NGT and obese-diabetic animals.  These genes may represent significant 
factors in the pathophysiology of type 2 diabetes.  Two gene discovery 
experiments were conducted using suppression subtractive hybridisation 
(SSH) to enrich a cDNA library for differentially expressed genes.   
 
Experiment 1 used cDNA dot blots to screen 576 clones with cDNA derived 
from lean-NGT and obese-diabetic animals.  6 clones were identified as 
overexpressed in lean-NGT animals and 6 were overexpressed in obese-
diabetic animals.  These 12 clones were sequenced and SYBR-Green PCR was 
used to confirm differential gene expression.  4 genes were overexpressed 
(>1.5 fold) in lean-NGT animals and 4 genes were overexpressed (>1.5 fold) 
in obese-diabetic animals.   
 
To explore the physiological role of these genes, hepatic gene expression was 
examined in several physiological conditions.  One gene, encoding thyroxine 
binding globulin (TBG), was confirmed as overexpressed in lean-NGT P. 
obesus with ad libitum access to food, relative to both obese-IGT and obese-
diabetic animals.  TBG expression decreased with fasting in all animals.  
Fasting TBG expression remained greater in lean-NGT animals than obese-
IGT and obese-diabetic animals.  TBG expression was not significantly 
affected by dietary energy restriction.  TBG is involved in thyroid metabolism 
and is potentially involved in the regulation of energy expenditure.   
 
Fasting increased hepatic site 1 protease (S1P) expression in lean-NGT 
animals but was not significantly affected in obese-IGT and obese-diabetic 
animals.  S1P expression was not significantly affected by dietary energy 
restriction.  S1P is involved in the proteolytic processing of steroid response 
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element binding proteins (SREBP).  SREBPs are insulin responsive and are 
known to be involved in lipid metabolism.                                            
 
Gene expression studies found TBG and S1P were associated with obesity and 
diabetes.  Future research will determine whether TBG and S1P are important 
in the pathogenesis of these diseases. 
 
Experiment 2 used SSH and cDNA microarray to screen 8064 clones.  223 
clones were identified as overexpressed in lean-NGT P. obesus and 274 clones 
were overexpressed in obese-diabetic P. obesus (p<0.05).  The 9 most 
significantly differentially expressed clones identified from the microarray 
screen were sequenced (p<0.01).  7 novel genes were identified as well as; 
sulfotransferase related protein and albumin.  These 2 genes have not 
previously been associated with either type 2 diabetes or obesity.  It is unclear 
why hepatic expression of these genes may differ between lean-NGT and 
obese-diabetic groups of P. obesus.  Subsequent studies will explore the 
potential role of these novel and known genes in the pathophysiology of type 2 
diabetes. 
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Literature Review 
 
1.1 TYPE 2 DIABETES MELLITUS 
1.1.1 Definition and Diagnosis 
Type 2 diabetes mellitus is a metabolic disease characterised by defects in 
insulin secretion and insulin action, and disturbances in carbohydrate, fat and 
protein metabolism that result in hyperglycemia (ADA, 2000).  Symptoms 
associated with type 2 diabetes may include polyuria, polydipsia and weight 
loss which may be accompanied by polyphagia (ADA, 2000).  Type 2 diabetes 
accounts for over 85 percent of all cases of diabetes worldwide (WHO, 1994).  
Impaired glucose tolerance (IGT) is a metabolic stage between normal glucose 
homeostasis and diabetes.  IGT is a major risk factor for the subsequent 
development of type 2 diabetes (ADA, 2000).  
 
The World Health Organisation (WHO) define diabetes and IGT based on 
plasma glucose concentrations following overnight fasting and/or two hours 
after a 75g glucose load assessed by an oral glucose tolerance test (OGTT).  
The WHO criteria are outlined below (WHO, 1994). 
 
Table 1.1.  WHO criteria for classification of diabetes mellitus (WHO, 1994). 
Venous Plasma Glucose (mmol/L)  
Fasting  2-hour post 
OGTT 
Normal Glucose Tolerance (NGT) <7.8 AND <7.8 
Impaired Glucose Tolerance (IGT) <7.8 AND 7.8-11.0 
Type 2 Diabetes >7.8 OR >11.0 
 
Type 2 diabetes is associated with an increased risk of mortality, and is among 
the five leading causes of death in most developed countries (Caterson and 
Zimmet, 1997).  Furthermore the increased morbidity accompanying type 2 
diabetes is associated with complications including; hypertension and 
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macrovascular diseases such as ischemic heart disease, stroke, peripheral 
vascular damage, as well as microvascular complications including 
retinopathy, neuropathy and nephropathy (Klein, 1995).  Within Australia the 
annual cost of diabetes is estimated to be A$1 billion (McCarty et al., 1996). 
 
The metabolic syndrome, also referred to as syndrome X, represents a group 
of metabolic disorders that are risk factors for cardiovascular disease (Reaven, 
1988; Zimmet et al., 2001).  Definition of the metabolic syndrome has 
recently been refined as; the presence of glucose intolerance (including type 2 
diabetes, IGT or insulin resistance) and at least two of the following; 
hypertension, obesity dyslipidemia or microalbuminuria (Alberti and Zimmet, 
1998).  Hyperuricaemia, hypercoagulability and hyperleptinaemia have also 
been proposed as components of the metabolic syndrome (Zimmet et al., 
2001).  Insulin resistance has been proposed as one of the key components of 
the metabolic syndrome.   
 
1.1.2 Prevalence 
The prevalence of type 2 diabetes is increasing rapidly worldwide, with an 
estimated 150 million people currently affected, and the prevalence expected 
to increase by 40 percent by 2010 (McCarty and Zimmet, 1994).  Type 2 
diabetes occurs in almost all populations, although prevalence rates vary 
considerably (King and Rewers, 1993).  The recent AusDiab study found the 
prevalence of type 2 diabetes in Australian men and women to be 8 percent 
and 6.8 percent respectively (Dunstan et al., 2002).  A similar prevalence rates 
is seen in the American population (Mokdad et al., 2000).   
 
The prevalence of type 2 diabetes is substantially higher in many “traditional” 
populations that have adopted a “modern” lifestyle including Nauruans (41%) 
(Dowse et al., 1991) and Pima Indians (50%) (Knowler et al., 1990), with the 
latter displaying the highest known prevalence of type 2 diabetes worldwide.  
Estimates of the prevalence of diabetes in Australian Aborigines have ranged 
from 4.5 to 12.7 % (Guest and O'Dea, 1992). 
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The prevalence of insulin resistance in subjects with one or more components 
of the metabolic syndrome was examined in the Bruneck Study (Bonora et al., 
1998).  Insulin resistance was present in the majority of subjects with type 2 
diabetes (83.9%), IGT (65.9%) and hypertension (58.0%).  Insulin resistance 
was also common in subjects with dyslipidemia (hypercholesterolemia, low 
HDL cholesterol or hypertriglyceridemia).  Furthermore, the prevalence of 
insulin resistance increased when subjects displayed more than one metabolic 
disturbance (Bonora et al., 1998).   
 
A large scale prospective study in Botnia examined the risk of CVD in 
subjects with the metabolic syndrome as defined above (Isomaa et al., 2001).  
In women and men, respectively, the metabolic syndrome was seen in 10 and 
15% of subjects with NGT, 42 and 64% of those with impaired fasting glucose 
or IGT, and 78 and 84% of those with type 2 diabetes. The risk for coronary 
heart disease and stroke was increased threefold and cardiovascular mortality 
was increased fivefold in subjects with the syndrome (Isomaa et al., 2001). 
 
1.1.3 Aetiology 
The rapid increase in the incidence of both obesity and type 2 diabetes in 
“traditional populations” such as the Pima Indians and Nauruans parallels the 
modernisation of their lifestyle.  The “thrifty genotype” hypothesis, originally 
proposed by Neel (1962), suggests that evolution has favored individuals who 
could efficiently store food energy as fat during periods where food supplies 
were plentiful, as they were better equipped to survive the subsequent periods 
of famine.  This “thrifty genotype” has become disadvantageous with the 
transition from a “traditional” to a “modern” lifestyle, which is characterised 
by a constant supply of food.  The increased consumption of energy dense 
foods with a concomitant decrease in physical activity in the current 
environment has resulted in a rapid increase in the incidence of obesity and 
type 2 diabetes (Zimmet et al., 1990).  Both genetic and environmental factors 
contribute to the development of type 2 diabetes. 
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1.1.3.1 Genetic Factors 
Since the “thrifty genotype” hypothesis was first proposed 40 years ago, 
various studies have sought to determine the genetic contribution to the 
development of type 2 diabetes.   
 
Population studies have examined the effect of foreign admixture on the 
prevalence of diabetes in “traditional” populations.  Despite the same 
environment the prevalence of type 2 diabetes amongst full blooded Nauruans 
and those with Caucasian admixture were 83 and 17 percent respectively for 
subjects over the age of 60 (Serjeantson et al., 1983).  Similar results were 
found with Australian Aborigines (Williams et al., 1987) and Pima Indians 
(Knowler et al., 1990).   
 
Family studies have demonstrated an increased risk of developing type 2 
diabetes if a first degree relative is diabetic (Keen et al., 1982; Cheta et al., 
1990; Thomas et al., 1994).  A study in Pima Indians demonstrated an 
increased risk of developing type 2 diabetes if one parent was diabetic (2.3 
times) and even greater risk if both parents were diabetic (3.9 times) (Knowler 
et al., 1981).  However these studies may overestimate the heritability of type 
2 diabetes due to the difficulty in distinguishing between genetic factors and 
the shared family environment.   
 
Studies examining the concordance rates of type 2 diabetes between 
monozygotic twins, who share 100 percent of their genes, and dizygotic twins, 
who share only 50 percent, provide evidence of heritability without the 
influence of familial environmental effects.  Matsuda & Kuzuya (1994) found 
concordance rates in Japanese monozygotic and dizygotic twins were 87 and 
43 percent respectively.  A similar study in American monozygotic and 
dizygotic twins found concordance rates of 58 and 17 percent respectively 
(Newman et al., 1987).  Despite the lower concordance rates in the American 
twins, both of these studies demonstrated higher concordance rates between 
monozygotic twins, strongly suggesting that genetic factors contribute to the 
development of type 2 diabetes.   There is also evidence to suggest that insulin 
resistance is a heritable trait as twin studies have found insulin resistance 
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correlates within monozygotic twins, but not dizygotic twins (Lehtovirta et al., 
2000).   
 
Population, family and twin studies have all demonstrated the significance of 
genetic factors in the development of type 2 diabetes.  However, type 2 
diabetes is a heterogeneous disease with many subtypes and the mode of 
inheritance remains controversial (McCarthy and Menzel, 2001).   
 
Type 2 diabetes occurs more often when diabetes is present maternally rather 
than paternally (Pettitt et al., 1988; Alcolado and Alcolado, 1991; Thomas et 
al., 1994).  The “thrifty phenotype” hypothesis proposes that the intrauterine 
environment may contribute to the development of type 2 diabetes later in life 
(Hales and Barker, 1992).  Alternatively imprinting of maternal genes may 
occur, or the mitochondrial genome may be important as mitochondrial genes 
are inherited maternally.  Mutations have been described in mitochondrial 
DNA that cause a subtype of diabetes, which includes hearing loss (Ballinger 
et al., 1992; Reardon et al., 1992).  However, mitochondrial mutations are not 
a common cause of type 2 diabetes in the general population (McCarthy and 
Menzel, 2001). 
 
Maturity onset diabetes of the young (MODY) is a heterogeneous subtype of 
type 2 diabetes, which accounts for 2-5 percent of all cases of type 2 diabetes 
(Froguel, 1998).  MODY is characterised by autosomal dominant inheritance 
of diabetes with an early age of onset and a primary defect in insulin secretion 
(Froguel, 1998).  Five different variations of MODY have been described, and 
each is the result of a defect in a single gene.  MODY2 results from a 
glucokinase mutation (Froguel et al., 1992) and MODY4 results from a 
mutation in the insulin promoter factor 1 (Stoffers et al., 1997).  Mutations in 
the hepatocyte nuclear factors HNF-4α, HNF-1α and HNF-1β are responsible 
for MODY 1, 3 and 5 respectively (Yamagata et al., 1996a; Yamagata et al., 
1996b; Horikawa et al., 1997).  Recently discovered mutations in the 
transcription factor neurogenic differentiation 1/β-cell E-box transactivator 2 
(NeuroD1/Beta2) are a rare cause of MODY (Malecki et al., 1999).  
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Although specific genes have been identified as contributing to MODY and 
mitochondrial diabetes, the mode of inheritance and the genes involved in the 
more common forms of type 2 diabetes remain uncertain (McCarthy et al., 
1994).  
 
1.1.3.2 Environmental Factors 
The importance of environmental factors in the development of type 2 
diabetes has been demonstrated in a study of Pima Indians (Ravussin et al., 
1994).  Arizona Pima Indians have adopted a “modern” lifestyle and have the 
highest known prevalence of type 2 diabetes in the world (37% in females and 
54% in males).  In contrast Mexican Pima Indians continue to lead a 
“traditional” lifestyle and have very low prevalence of diabetes (11% in 
females and 6% in males).  This discrepancy is present despite the common 
genetic background of these two populations.  Therefore, an individual’s 
genotype can determine their susceptibility to developing type 2 diabetes, but 
environmental factors ultimately determine whether or not they become 
diabetic (Ravussin et al., 1994). 
 
The Nurses’ Health Study, a 16 year prospective study of 84,941 women 
found overweight or obesity was the most important predictor of type 2 
diabetes development.  Other important factors included; lack of exercise, a 
poor diet (high trans fat content and glycemic load, low in cereal fibre and low 
ratio of polyunsaturated to saturated fat), current smoking and abstinence from 
alcohol (Hu et al., 2001). 
 
Obesity is a major risk factor for type 2 diabetes.  Longitudinal studies have 
demonstrated an increased risk of developing type 2 diabetes in obese subjects 
relative to lean controls (Haffner et al., 1990; Everhart et al., 1992).  
Furthermore, this risk increases with the duration of obesity (Everhart et al., 
1992).  Central obesity is a strong risk factor for type 2 diabetes independent 
of total adiposity (Bergstrom et al., 1990; Haffner et al., 1990).  Therefore, 
both the accumulation and distribution of body fat are important factors in the 
development of type 2 diabetes.  Genetic factors are also involved in both the 
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accumulation and distribution of body fat (Bouchard et al., 1988; Bouchard et 
al., 1990; Allison et al., 1996). 
 
A high energy intake and in particular a high fat intake have been associated 
with the development of type 2 diabetes in cross sectional (Tsunehara et al., 
1990; Marshall et al., 1991) and longitudinal (Marshall et al., 1994) studies.  
Low levels of physical activity also increase the risk of subsequently 
developing type 2 diabetes, independent of obesity (Manson et al., 1992; 
Lynch et al., 1996; Hu et al., 1999).  A high energy, high fat diet combined 
with low levels of physical activity are important environmental factors 
contributing to the development of type 2 diabetes.  A high energy intake and 
low energy expenditure will also increase adiposity, further increasing the 
likelihood of developing diabetes.   
  
The nutrition principles recommended by the American Diabetes Association 
(ADA) for treatment and prevention of type 2 diabetes include; weight loss by 
reducing energy intake and increasing physical activity levels, and reducing 
total fat and saturated fat contents to less than 30 and 10 percent of total 
energy intake respectively (Franz et al., 2002).  Lifestyle interventions are 
likely to be particularly important for individuals with an increased genetic 
susceptibility to the development of diabetes.  Strategies to promote lifestyle 
changes within Western populations to reduce the prevalence of type 2 
diabetes have largely been ineffectual, as prevalence rates continue to increase 
(Zimmet et al., 2001).  Gene discovery studies can identify novel factors 
involved in the pathogenesis of type 2 diabetes, potentially leading to new 
therapeutic approaches. 
 
1.1.4 Regulation of Glucose Homeostasis 
Glucose is the primary fuel for the central nervous system (CNS), therefore 
blood glucose levels must be carefully regulated to ensure adequate supply to 
this essential organ.  The regulation of glucose homeostasis can be separated 
into two phases, that following the ingestion of an oral glucose load or mixed 
meal (postprandial) and that in the 6 to 12 hours ollowing ingestion 
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(postabsorptive).  Postprandial and postabsorptive glucose metabolism is 
summarised in Figure 1.1. 
Figure 1.1.  Glucose metabolism in the postprandial and postabsorptive 
phases (Dinneen et al., 1992). 
 
1.1.4.1 Postprandial Glucose Homeostasis 
Plasma glucose concentrations increase following glucose ingestion.  To 
utilise the available glucose and maintain plasma concentrations within the 
normal range three simultaneous processes occur; increased pancreatic insulin 
secretion, suppression of endogenous glucose production (predominantly 
liver), and increased glucose uptake in splanchnic tissues (liver and gut) and 
peripheral tissues (predominantly skeletal muscle and adipose tissue) 
(DeFronzo, 1992; Dinneen et al., 1992). 
 
The pancreas, skeletal muscle, adipose tissue, and liver are of primary 
importance in maintaining glucose homeostasis and defects in each of these 
tissues are potentially involved in the pathogenesis of type 2 diabetes.  
 
1.1.4.1.1 Pancreas 
Insulin and glucagon are the key pancreatic hormones responsible for 
maintaining glucose homeostasis.  The postprandial increase in plasma 
glucose signals the β-cells of the pancreas to secrete insulin, while suppressing 
glucagon secretion from the α-cells of the pancreas.   
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Following glucose ingestion, two distinct phases of insulin secretion occur.  
The first phase is characterized by a rapid rise in plasma insulin and is 
completed within 10 minutes.  The second phase begins within 10 to 20 
minutes of glucose ingestion and is of greater duration and magnitude (Pratley 
and Weyer, 2001).  Insulin stimulates glucose uptake in peripheral tissues and 
suppresses endogenous glucose production (EGP), thereby reducing plasma 
glucose concentrations (DeFronzo, 1992; Dinneen et al., 1992).    
 
The relationship between the plasma glucose concentration and the mean 
plasma insulin response to a 100g oral glucose load in normoglycemic, 
impaired glucose tolerant and hyperglycemic subjects resembles an inverted 
”U” shape, and is referred to as Starlings Curve of the pancreas (Figure 1.2) 
(DeFronzo, 1988).  This same relationship is seen between fasting plasma 
glucose and insulin concentrations with the progression from NGT to diabetes 
(DeFronzo et al., 1989).  As fasting plasma glucose concentrations increase, 
there is a progressive increase in insulin secretion. Overt diabetes is 
established as plasma glucose concentrations increase further and the 
compensatory increase in insulin secretion can not be maintained, leading to 
β-cells failure and a further increase in plasma glucose (DeFronzo, 1988).   
Figure 1.2.  Starling’s curve of the pancreas (DeFronzo, 1988). 
 
Several disturbances in insulin secretion occur with type 2 diabetes including 
delayed or blunted first phase insulin secretion and fasting hyperinsulinemia, 
indicative of insulin resistance.  Suppressing first phase insulin secretion with 
somatostatin has been shown to reduce intravenous glucose tolerance (Calles-
Escandon and Robbins, 1987).  The first phase insulin secretion is particularly 
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important for suppression of EGP (Luzi and DeFronzo, 1989) and may also 
prime insulin sensitive tissues for glucose uptake (Castillo et al., 1994). 
 
Several cross sectional studies have shown blunted or delayed first phase 
insulin secretion in subjects with type 2 diabetes (Meneilly et al., 1993), as 
well as those with IGT (Matsumoto et al., 1997) and the offspring of diabetic 
parents (Pimenta et al., 1995; Thorburn and Proietto, 1999).  Several 
longitudinal studies have shown that a low acute insulin secretory response is 
a predictor of diabetes development (Skarfors et al., 1991; Lillioja et al., 
1993), however, other studies have found conflicting results (Warram et al., 
1990; Martin et al., 1992).  A longitudinal study in Pima Indians found the 
acute insulin response declined 27 percent with the transition from NGT to 
IGT and another 51 percent with the transition from IGT to diabetes.  In 
contrast AIR increased 30 percent in subjects that did not progress to diabetes 
(Weyer et al., 1999).   
 
The eventual failure of the pancreas to sustain the hyperinsulinemia necessary 
to compensate for insulin resistance is a necessary step for the development of 
overt type 2 diabetes.  The cause of this pancreatic failure remains to be 
elucidated.  Hyperglycemia itself, or “glucotoxicity”, has been proposed as the 
cause of β-cell failure in type 2 diabetes (Garvey, 1992).  “Lipotoxicity” has 
also been suggested, as long term exposure of pancreatic islets to excess free 
fatty acids inhibits glucose induced insulin secretion and biosynthesis and may 
also lead to apoptosis (Unger, 1995). 
 
1.1.4.1.2 Peripheral and Hepatic Tissues 
Glucose clamp studies, which maintain the plasma insulin concentration at a 
fixed level, have been used to examine insulin stimulated glucose disposal 
under various glucose concentrations.  Del Prato et al (1993) performed three 
clamp studies in NGT and type 2 diabetic subjects.  Under euglycemic 
conditions glucose uptake was decreased in diabetic subjects. Glycolysis, 
glycogen synthesis, and glucose oxidation were reduced and nonoxidative 
glycolysis and lipid oxidation were increased.  Hyperglycemia and 
 13
LITERATURE REVIEW 
hyperinsulinemia were each able to normalise whole body glucose uptake in 
diabetic subjects. Hyperinsulinemia also normalised glycogen synthesis and 
lipid oxidation but did not normalise the reduced glucose oxidation or the 
increased nonoxidative glycolysis.  Hyperglycemia increased glycogen 
synthesis, but did not normalise the defects in glucose and fat oxidation or 
nonoxidative glycolysis.  These studies highlighted multiple defects in glucose 
metabolism, some of which can be overcome by hyperinsulinemia and 
hyperglycemia. 
 
Quantitatively, glucose clamp studies have generally found reduced glucose 
disposal, predominately skeletal muscle to be the most important determinate 
of hyperglycemia in type 2 diabetic subjects.  Reduced suppression of EGP 
and reduced splanchnic glucose uptake only made minor contributions to 
hyperglycemia (DeFronzo et al., 1985; Golay et al., 1988a; Golay et al., 
1988b; Del Prato et al., 1993).   
 
Several studies have examined glucose disposal following an oral glucose load 
or mixed meal.  Postprandial glucose appearance is elevated in type 2 diabetic 
subjects, relative to NGT controls (Firth et al., 1986; Ferrannini et al., 1988; 
McMahon et al., 1989; Mitrakou et al., 1990; Fery et al., 1993; Kelley et al., 
1994).  However, controversy exists over the relative contribution of reduced 
glucose disposal and elevated EGP to postprandial hyperglycemia.  
 
Kelley et al (1994) examined type 2 diabetic and controls subjects following a 
mixed meal.  Cumulative glucose appearance over the 5 hour period was 
elevated in the diabetic subjects and was entirely due to reduced suppression 
of EGP.  Cumulative glucose utilisation and oxidation were not different to 
control subjects, nor was splanchnic glucose uptake.  Similar results were seen 
by Fery et al (1993) following a 75g glucose load.  Cumulative glucose 
disposal over the entire 5 hour period was not different to controls, and the 
increased glucose appearance was entirely due to elevated EGP.  Mitrakou et 
al (1990) also found a reduced suppression of EGP in diabetic subjects after a 
75g glucose load, with no difference in skeletal muscle glucose uptake 
between groups.  Type 2 diabetic subjects displayed reduced splanchnic 
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glucose uptake in the study by (Mitrakou et al., 1990), however this was not 
found in other studies.   
 
Elevated EGP was also found in type 2 diabetic subjects in a number of other 
studies (Firth et al., 1986; Ferrannini et al., 1988; McMahon et al., 1989; Fery 
et al., 1993).  Ferrannini et al (1988) found that reduced postprandial glucose 
utilisation in diabetic subjects was quantitavely more important than elevated 
EGP following an oral glucose load, however the duration of this study was 
3.5 hours, compared to 5 hours for the studies described above.   
 
Taken together the results of these studies indicate both hepatic and peripheral 
disturbances contribute to postprandial hyperglycemia.   
 
Quantitatively studies examining oral disposal of glucose or mixed meals 
attribute a greater proportion of postprandial hyperglycemia to hepatic defects 
than those studies utilising the glucose clamp technique.  Although glucose 
clamp studies are often considered to be the gold standard for assessing insulin 
resistance, the methodological differences between these two measures of 
insulin stimulated glucose metabolism limit the conclusions that can be drawn 
regarding peripheral glucose disposal and EGP in free living subjects.   
 
Within the liver insulin suppresses EGP by decreasing the transcription of 
gluconeogenic enzymes encoding phosphoenol puruvate carboxykinase 
(PEPCK), fructose 1,6 bisphosphatase and glucose 6-phosphatase.  Insulin 
also decreases the transcription of glycolytic enzymes including glucokinase 
and pyruvate kinase and lipogenic enzymes including fatty acid synthase and 
acetyl CoA carboxylase (Saltiel and Kahn, 2001).  Insulin may regulate the 
transcription of many of these enzymes via sterol regulating element binding 
proteins (SREBP), which are insulin responsive transcription factors involved 
in fat and cholesterol metabolism (Osborne, 2000). 
 
Insulin not only regulates glucose metabolism directly through actions on 
hepatic and peripheral tissues, but indirectly through actions on fat 
metabolism.  In adipose tissue lipolysis is inhibited by insulin (Swislocki et 
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al., 1987).  Adipose tissue is also insulin resistant in type 2 diabetic subjects 
and is associated with increased triglyceride breakdown and elevated plasma 
free fatty acid (FFA) concentration (Golay et al., 1987; Skowronski et al., 
1991).  An elevated FFA concentration could contribute to peripheral and 
hepatic insulin resistance. 
 
Insulin resistance is also associated with obesity, particularly central obesity.  
Approximately 40 percent of overweight subjects are insulin resistant, and 
insulin resistance increases with weight gain and decreases with weight loss 
(Ferrannini et al., 1991; Ferrannini et al., 1997).  Central obesity has also been 
associated with insulin resistance.  Central adipose stores have a greater 
proportion of visceral adipose tissue, which is more metabolically active than 
subcutaneous adipose tissue (Montague and O'Rahilly, 2000).  Visceral 
adipose tissue drains directly to the liver via the portal vein contributing to 
hepatic insulin resistance (Kissebah and Krakower, 1994).  The liver is 
therefore exposed to an increased flux of FFA and precursors for glucose 
synthesis, promoting hepatic glucose production and VLDL secretion. 
 
Elevated plasma FFA concentration can lead to hepatic accumulation of 
triglycerides and fatty acid derived metabolites, including diacylglycerol, fatty 
acyl CoA and ceramides, with net effect being the induction of hepatic insulin 
resistance (Kim et al., 2001; Kelley and Goodpaster, 2001).  The increased 
hepatic FFA availability contributes to elevated EGP (Ferrannini et al., 1983; 
Rebrin et al., 1995) due to increased gluconeogenesis (Morand et al., 1993).  
The elevated plasma FFA concentration, along with hyperinsulinemia, also 
increases hepatic very low density lipoprotein (VLDL) triglyceride secretion 
(Malmstrom et al., 1997).  Hepatic glucose and fat metabolism are therefore 
interdependent. 
 
An elevation in plasma FFA concentration also inhibited insulin stimulated 
glucose disposal in skeletal muscle of normoglycemic and hyperglycemic 
subjects (Boden et al., 1994; Boden and Chen, 1995).  This reduced glucose 
disposal was found to be due to reduced glucose uptake and subsequently 
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reduced glucose oxidation and glycogen synthesis (Boden et al., 1994; Boden 
and Chen, 1995).   
  
In summary, reduced suppression of EGP is a major cause of postprandial 
hyperglycemia.  Reduced peripheral glucose disposal also contributes to the 
elevated blood glucose levels.  Increased lipolysis in adipose tissue contributes 
to hepatic and peripheral insulin resistance. 
 
1.1.4.2 Postabsorptive Glucose Homeostasis 
During the postabsorptive phase glucose homeostasis is dependent on the 
balance between whole body glucose disposal and endogenous glucose 
production (predominantly by the liver).  In normoglycemic subjects EGP is 
approximately 2mg/kg/min (DeFronzo, 1988).  Approximately 75-80 percent 
of postabsorptive glucose disposal is non-insulin dependent and predominantly 
occurs in the CNS and splanchnic tissues.  The remaining 20-25 percent of 
glucose disposal is insulin dependent and occurs in peripheral tissues, 
predominantly skeletal muscle and also adipose tissue (DeFronzo et al., 1985; 
Baron et al., 1988; Ferrannini and Groop, 1989).   
 
Glucagon stimulates gluconeogensis and EGP as well as lipolysis.  Del Prato 
et al (2002) has suggested type 2 diabetic subjects may display elevated 
plasma glucagon concentrations and may also have increased sensitivity to the 
hormone.  These disturbances could increase EGP, contributing to 
hyperglycemia in type 2 diabetic subjects.  However, a causative relationship 
between elevated plasma glucagon and hyperglycemia has not been 
established.  
 
Several studies have examined whole body glucose oxidation rates in the 
postabsorptive phase.  Bogardus et al (1984) found glucose oxidation to be 
reduced and fat oxidation to be increased in type 2 diabetic subjects.  Similarly 
Franssila-Kallunki and Groop (1992) found increased fat oxidation.  However, 
other studies have found whole body glucose oxidation and fat oxidation rates 
in diabetic and subjects to be similar to NGT subjects (Vaag et al., 1992; Fery 
et al., 1993; Kelley et al., 1994).   Postabsorptive hyperglycemia in type 2 
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diabetes is therefore unlikely to be due to systemic reduction in glucose 
oxidation. 
 
Basal metabolic rate (BMR), expressed relative to FFM, is increased type 2 
diabetic subjects (Bogardus et al., 1986b; Franssila-Kallunki and Groop, 
1992). Furthermore, when glycaemic control is improved either 
pharmacologically or with a reduced energy intake, BMR is often reduced 
(Ravussin et al., 1983; Bogardus et al., 1986b; Franssila-Kallunki and Groop, 
1992). BMR correlates with EGP (Franssila-Kallunki and Groop, 1992), 
suggesting elevated gluconeogenesis, which is an energy expensive process, is 
likely to contribute to the elevated BMR in type 2 diabetes (Franssila-Kallunki 
and Groop, 1992).  
 
Glucose uptake by the CNS is not different between diabetic and control 
subjects in absolute terms, which is not surprising given the importance of a 
constant regular supply of glucose to this organ (Grill, 1990).  Fasting 
hyperglycemia must therefore result from reduced peripheral glucose disposal 
or increased EGP.   
 
1.1.4.2.1 Peripheral Tissues  
Skeletal muscle is responsible for the majority of peripheral glucose 
utilisation.  In the postabsorptive phase plasma glucose and insulin levels are 
low, inhibiting glucose uptake into skeletal muscle and adipose tissue.  
Therefore, in postabsorptive conditions fat is preferentially oxidised, utilising 
plasma FFA and intramuscular triglyceride stores, with glucose oxidation 
predominately utilising intramuscular glycogen stores (Groop et al., 1991; 
Felber and Golay, 1995).  Hyperglycemia in type 2 diabetes is accompanied 
by hyperinsulinemia, indicating type 2 diabetic subjects have a defect in 
insulin mediated glucose uptake in skeletal muscle.   
 
Fery et al (1993) found postabsorptive hyperglycemia in severely diabetic 
subjects was due to both elevated EGP and reduced glucose disposal.  Similar 
results were seen in other studies (Firth et al., 1986; Ferrannini et al., 1988).  
In contrast, studies of moderately diabetic subjects have found reduced 
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glucose clearance (glucose utilisation divided by plasma glucose 
concentration) (DeFronzo et al., 1989; Hother-Nielsen and Beck-Nielsen, 
1991; Fery et al., 1993).  Furthermore, these studies failed to detect any 
elevation in EGP suggesting peripheral, predominantly skeletal muscle, insulin 
resistance is the primary cause of fasting hyperglycemia in the early stages of 
type 2 diabetes.   
 
DeFronzo (1992) suggested that the fasting hyperinsulinemia that 
accompanies moderate type 2 diabetes is inadequate to stimulate whole body 
glucose uptake but adequate to suppress EGP.  This conclusion is supported 
by the relationship between EGP and fasting plasma glucose demonstrated by 
DeFronzo (1988).  EGP was not correlated with fasting plasma glucose in 
normoglycemic or moderately diabetic subjects, however a significant positive 
correlation was found in overtly diabetic subjects.  DeFronzo (1988) suggested 
that EGP increases significantly with the reduction in plasma insulin 
concentration that accompanies the development of overt diabetes. 
 
1.1.4.2.2 Liver 
Although many studies have demonstrated that increased EGP is a major 
cause of fasting hyperglycemia in overt diabetes (Bogardus et al., 1984; 
DeFronzo, 1988; Gerich, 1991; Kelley et al., 1994; Perriello et al., 1997), the 
relative contribution of increased EGP in the progression from normoglycemia 
to moderate diabetes remains controversial.  Gerich (1991) demonstrated 
increased EGP in subjects with plasma glucose concentrations of 6-7 mmol/L.  
A subsequent study by Perriello et al (1997) with normoglycemic and 
moderately diabetic (plasma glucose <7.8 mmom/L) and overtly diabetic (≥7.8 
mmol/L) subjects demonstrated increased EGP in both diabetic groups.  
However, normal rates of fasting EGP have been found in other studies of 
mildly diabetic subjects (DeFronzo, 1988; Kelley et al., 1994).  
 
Disturbances in hepatic glucose metabolism are evident in the progression 
from normoglycemia to moderate fasting hyperglycemia even if absolute EGP 
is not increased.  The liver must be insulin and glucose resistant in moderate 
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diabetic subjects as, this condition is characterised by elevated plasma glucose 
and insulin concentrations, both of which normally act to suppress EGP 
(DeFronzo et al., 1983).  EGP is therefore increased relative to plasma glucose 
and insulin concentrations in the early stages of the development of type 2 
diabetes, and increases further as hyperglycemia worsens.   
 
EGP is the result of both glycogenolysis and gluconeogenesis.  Defects in 
either of these pathways could account for the increased postprandial and 
postabsorptive EGP that occurs in type 2 diabetes.  Glycogenesis is catalysed 
by glycogen synthase. Glycogenolysis is catalysed by the enzyme glycogen 
phosphorylase.  Glycogen synthase and phosphorylase therefore jointly 
coordinate glycogen synthesis and degradation and contribute to the regulation 
of EGP.  Gluconeogenesis utilises non-carbohydrate precursors including 
lactate from anaerobic glycolysis, alanine and glutamine from amino acid 
metabolism and glycerol from lipolysis, to synthesise glucose (Dinneen et al., 
1992).  PEPCK is the rate-limiting enzyme in gluconeogenesis.  Other key 
enzymes in gluconeogenesis include fructose 1,6-biphosphatase and glucose 6 
phosphatase. 
 
Type 2 diabetic subjects have been shown to have increased gluconeogenesis 
during the postprandial (Nurjhan et al., 1986) and postabsorptive (Consoli and 
Nurjhan, 1990; Magnusson et al., 1992; Perriello et al., 1997) phases.  Consoli 
& Nurjhan (Consoli and Nurjhan, 1990) demonstrated a threefold increase in 
gluconeogenesis in type 2 diabetic subjects compared to controls, which 
accounted for 80 percent of the increased EGP.  Fasting hyperglycemia in 
these subjects was positively correlated with gluconeogenesis but not 
glycogenolysis.  The gluconeogenic pathway is therefore primarily responsible 
for the elevated postabsorptive EGP, and may also predominate 
postprandially.  Increased conversion of both lactate and alanine to glucose 
have been associated with the elevated gluconeogenesis in type 2 diabetic 
subjects (Consoli et al., 1990; Nurjhan et al., 1992).  Elevated 
gluconeogenesis in type 2 diabetes is due to both an increased supply of 
gluconeogenic precursors and increased efficiency of substrate conversion in 
the liver (Consoli et al., 1990). 
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In summary, postabsorptive hyperglycemia is due to increased EGP as well as 
reduced peripheral glucose disposal.  The former may become quantitatively 
more important as fasting glucose concentrations increase.  Increased 
gluconeogenesis is likely to be the principal cause of the elevated EGP, 
although glycogenolysis may also contribute.  
 
1.1.4.3 Dynamic Glucose Homeostasis  
Daily maintenance of glucose homeostasis is dependent on the postabsorptive 
regulation of whole body glucose metabolism and the postprandial disposal of 
mixed meals.  There is evidence to suggest diurnal variations in insulin 
secretion and insulin sensitivity also influence glucose homeostasis.  
 
Boden et al (1996b) examined insulin secretion in normoglycemic subjects 
with plasma glucose clamped at 5, 8.8 and 12.6 mmol/L for 68 hours.  Serum 
insulin concentration changed in a circadian (approximately 24 hour) rhythm, 
increasing from a nadir between midnight and 6:00AM and reaching a peak 
between noon and 6:00PM.   
 
A subsequent study found this circadian rhythm in insulin secretion was 
absent in type 2 diabetic subjects during a hyperglycemic clamp (11.1 
mmol/L) (Boden et al., 1996a).  However, glucose infusion rate, reflecting 
insulin sensitivity, displayed circadian (approximately 24 hour) rhythm, 
increasing from a nadir in the morning (approximately 8:00AM) to a peak in 
the evening (approximately 7:00PM).  The decrease in GIR was due to 
increased EGP rather than decreased glucose disposal.  FFA and cortisol levels 
may have contributed to the circadian changes in EGP as these variables were 
correlated (Boden et al., 1996a).   
 
Disturbances in circadian insulin secretion may be secondary to the metabolic 
abnormalities associated with type 2 diabetes.  However, there is evidence to 
suggest that NGT first degree relatives of type 2 diabetic subjects have 
disturbances in circadian insulin secretion, suggesting these disturbances may 
contribute to the development of type 2 diabetes (Boden et al., 1999).  
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In summary, the development of hyperglycemia in type 2 diabetes is primarily 
due to insulin resistance, although pancreatic failure and insulin deficiency 
occurs as insulin sensitivity decreases and the blood glucose concentration 
increase further.  Insulin resistance is evident in peripheral and hepatic tissues.  
Elevated EGP and reduced suppression of EGP are likely to contribute 
substantially to the postabsorptive and postprandial hyperglycemia 
respectively.  Reduced peripheral glucose disposal also contributes to the 
hyperglycemia in type 2 diabetes.  Insulin resistance in adipose tissue results 
in increased lipolysis and elevated FFA concentrations.  The increased plasma 
FFA concentration is likely to contribute to both hepatic and peripheral insulin 
resistance, increasing EGP and reducing glucose disposal respectively.  EGP is 
responsible for the diurnal variation in glucose homeostasis in type 2 diabetes. 
 
1.2 GENE DISCOVERY IN TYPE 2 DIABETES  
The establishment of a genetic component to the development of type 2 
diabetes has stimulated research to identify these genes.  Several different 
gene discovery strategies have been utilised, including candidate gene 
approaches, genome wide scans and gene expression approaches.   
 
1.2.1 Candidate Gene Approaches 
Candidate gene approaches identify a gene based on a biological function, and 
attempt to establish a relationship between variation within the gene and a 
phenotype.  Association studies may examine the frequency of a 
polymorphism within a candidate gene in diabetic and non-diabetic subjects or 
examine the relationship between the polymorphism and linear variables such 
as plasma glucose concentrations.  The polymorphism examined may be 
directly involved in the development of the disease, or in linkage 
disequilibrium with a causative mutation.  These studies are limited, as they 
require initial knowledge of the disease process. 
 
Another candidate gene approach involves manipulating the gene of interest 
and examining the phenotypic changes that occur.  Gene expression can be 
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increased using transgenic techniques or alternatively gene expression can be 
reduced or abolished using antisense and gene knockout techniques.  These 
genetic manipulations can be specific to a tissue of interest.  Although these 
studies are useful, they create a non-physiological condition, limiting the 
relevance to pathogenesis of the human disease.   
 
Disturbances in hepatic glucose metabolism contribute to the development of 
type 2 diabetes.  Genes expressed in the liver which encode proteins involved 
in insulin signaling, glucose uptake and release, glycolysis, gluconeogenesis 
and glycogen synthesis and degradation are all candidates for contributing to 
the development of type 2 diabetes.  Several key genes are discussed below. 
 
1.2.1.1 Insulin Receptor 
Insulin receptor knockout mice develop severe diabetes with defects in the 
pancreas, skeletal muscle, adipose tissue and liver, including reduced hepatic 
glycogen stores (Cinti et al., 1998).  Muscle specific insulin receptor knockout 
mice remain glucose tolerant, suggesting other tissues, such as liver, are 
important in glucose disposal in this animal (Bruning et al., 1998).  In contrast 
liver specific insulin receptor knockout mice are hyperinsulinemic with severe 
insulin resistance and develop diabetes by the age of 2 months.  However, 
fasting hyperglycemia returned to normal by the age of 4 months (Michael et 
al., 2000).  Although the knockout of liver insulin receptors is not sufficient to 
produce sustained diabetes, these studies have demonstrated the importance of 
insulin receptors in the liver in maintaining glucose homeostasis. 
 
The insulin receptor gene is located on chromosome 19p13.3-13.2.  Several 
linkage studies have failed to detect linkage with mutations in the insulin 
receptor and type 2 diabetes (Elbein et al., 1988; O'Rahilly et al., 1988; Cox et 
al., 1989; Elbein and Sorensen, 1991; Elbein et al., 1992b).  Association 
studies in Mexican Americans (Raboudi et al., 1989) and Caucasian, Hispanic 
and Chinese Americans (McClain et al., 1988; Xiang et al., 1989) have found 
an association between insulin receptor polymorphisms and type 2 diabetes.  
However several studies with these and other mutations have failed to find an 
association with type 2 diabetes (Takeda et al., 1986; Hitman et al., 1987; 
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Elbein, 1989; Morgan et al., 1990; Oelbaum et al., 1991; Sten-Linder et al., 
1991).  Mutations in the insulin receptor are therefore unlikely to be a 
common cause of type 2 diabetes. 
 
1.2.1.2  Insulin Receptor Substrates  
Insulin receptor substrate (IRS)-1 is the major substrate of the insulin receptor 
as well as the insulin like growth factor receptors.  IRS-1 knockout mice are 
insulin resistant in skeletal muscle, but maintain normal glucose levels (Araki 
et al., 1994; Tamemoto et al., 1994).  Hepatic insulin resistance is prevented 
by IRS-2 compensation (Patti et al., 1995).  IRS-2 knockout mice develop 
mild to severe diabetes with reduced β-cell mass (Kubota et al., 2000).  
Muscle remains insulin sensitive, while the liver is insulin resistant.  IRS-1 
does not compensate for defective hepatic IRS-2 (Kubota et al., 2000).  IRS-2 
may therefore be an important component of hepatic insulin signaling. 
 
The IRS-2 gene is located on chromosome 13q34.  A common non-
conservative amino acid substitution (G1057D) within IRS-2 was associated 
with type 2 diabetes increased in Italian subjects (Mammarella et al., 2000), 
however this has not been confirmed in other studies (Fritsche et al., 2001; 
Wang et al., 2001).  Other association and linkage studies with IRS-2 and type 
2 diabetes have also been negative (Kalidas et al., 1998; Almind et al., 1999; t 
Hart et al., 2002).  Mutations in IRS-2 are therefore unlikely to be a common 
cause of type 2 diabetes. 
 
1.2.1.3 Glucose transporters  
The glucose transporter family includes five different transporters (GLUT1-5), 
each with different tissue distribution and chromosomal location.  GLUT2 is 
the liver and pancreas isoform and is located on chromosome 3q26.1-26.3 
(Thorens et al., 1988).  GLUT2 is involved in hepatic glucose uptake and 
release (Pessin and Bell, 1992).   
 
An association study in Caucasians British subjects found a significant 
association between a Taq I polymorphism in GLUT2 and type 2 diabetic 
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subjects with a family history of diabetes (Alcolado et al., 1991).  A linkage 
study in Pima Indians found weak linkage between GLUT2 and acute insulin 
response but not type 2 diabetes (Janssen et al., 1994).  Several other 
association and linkage studies have failed to find an association between 
GLUT2 and type 2 diabetes (Matsutani et al., 1990; Li et al., 1991b; Patel et 
al., 1991; Baroni et al., 1992; Elbein et al., 1992a; Moller et al., 2001).  One 
patient has been identified with diabetes caused by a mutation in GLUT2, 
although the diabetes in this patient was thought to be caused by a β-cell 
defect (Mueckler et al., 1994).  Mutations in GLUT2 are unlikely to be a 
common cause of type 2 diabetes. 
 
1.2.1.4 Glucokinase 
Glucose entering the hepatocyte through GLUT2 is converted to glucose 6 
phosphate by glucokinase.  This reaction maintains low intracellular glucose 
concentrations and facilitates glucose uptake (Matschinsky, 1990).  
Glucokinase may also regulate glucose release (Matschinsky, 1990).  A 
transgenic study expressing human glucokinase in the liver of mice reduced 
fasting glucose, insulin and lactate levels and improved glucose tolerance 
(Hariharan et al., 1997). 
 
The glucokinase gene is located on chromosome 7p13.  A mutation in 
glucokinase is responsible for MODY2 (Froguel et al., 1992), therefore many 
studies have examined glucokinase mutations in the common form of type 2 
diabetes.  A study in African Americans found the Z+4 allele was associated 
with an increased risk of developing type 2 diabetes and a younger onset of 
diabetes (Chiu et al., 1992b).  The Z+2 allele increased the risk of developing 
diabetes in Mauritian Creoles (Chiu et al., 1992a).  Other variants have been 
associated with insulin sensitivity (Elbein et al., 2001) and hepatic insulin 
sensitivity (Chiu et al., 2000b).  However studies in Pima Indians, and 
American, British and French Caucasians did not find association with these 
or other mutations in the glucokinase gene (Matsutani et al., 1992; Permutt et 
al., 1992).  Linkage studies with glucokinase have also been negative (Cook et 
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al., 1992; Permutt et al., 1992; Stoffel et al., 1992).  Glucokinase mutations 
are therefore unlikely to be a common cause of type 2 diabetes.  
 
1.2.1.5 Phosphoenol Puruvate Carboxykinase  
Phosphoenol pyruvate carboxykinase (PEPCK) is expressed in liver and 
kidneys as well as adipose tissue and the small intestine (Beale et al., 1985).  
PEPCK converts oxaloacetate to phosphoenol pyruvate and is the rate limiting 
enzyme in gluconeogenesis (Rognstad, 1979).  Several studies have 
demonstrated increased gluconeogenesis in type 2 diabetes (Consoli and 
Nurjhan, 1990; Perriello et al., 1997).  PEPCK is located on chromosome 
20q13.31.  An association study failed to find any mutations in the promoter 
region of PEPCK (Ludwig et al., 1996).  Mutations in the PEPCK gene are yet 
to be associated with type 2 diabetes. 
 
1.2.1.6 Glycogen Synthase 
Glycogen synthase is the key enzyme in glycogenesis and therefore the 
storage of glucose in both liver and muscle.  The glycogen synthase gene is 
located on chromosome 19.  A study of Finnish subjects found an association 
between the Xba I polymorphism in the glycogen synthase gene and type 2 
diabetes (Groop et al., 1993).  However several other studies have failed to 
find an association between this and other polymorphisms in glycogen 
synthase and type 2 diabetes (Kadowaki et al., 1993; Zouali et al., 1993; 
Wang et al., 1998).  Type 2 diabetes is unlikely to result from mutations in 
glycogen synthase in most cases.  
 
1.2.1.7 Hepatocyte Nuclear Factors  
Hepatocyte Nuclear Factors (HNF’s) are expressed in the liver and to a lesser 
extent in the pancreas, kidney and gut (Blumenfeld et al., 1991; Pontoglio et 
al., 1996).  Mutations in the HNF isoforms 1α, 1β and 4α result in the 
development of MODY (Yamagata et al., 1996a; Yamagata et al., 1996b; 
Horikawa et al., 1997).  MODY is characterised by reduced insulin secretion, 
rather than insulin resistance implicating the pancreas rather than the liver in 
this form of diabetes (Froguel, 1998).  Nevertheless, HNF’s are involved in 
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hepatocyte differentiation and are transcription factors for many liver specific 
enzymes involved in glucose and fat metabolism including PEPCK (Stoffel 
and Duncan, 1997).   
 
HNF-1α knockout mice develop dwarfism and diabetes due to reduced IGF-1 
and insulin.  Disturbances of hepatic glucose metabolism are evident with 
accumulation of complex carbohydrate, thought to be glycogen in hepatocytes 
(Lee et al., 1998).  Homozygote knockouts of liver HNF-4α die during 
embryogenesis.  Heteroygotes do not develop diabetes, although they have 
disturbances of lipid homeostasis with increased hepatic lipid storage and 
reduced circulating lipids (Hayhurst et al., 2001). 
 
Associations studies with HNF genes have been conducted in many 
populations.  Mutations in HNF1α have been associated with; type 2 diabetes 
in Finns (Rissanen et al., 2000), early onset of type 2 diabetes in American 
subjects (Triggs-Raine et al., 2002) and insulin sensitivity in Oji-Cree 
Canadians (Chiu et al., 2000a).  However, several other studies with these and 
other mutations have failed to find any association with type 2 diabetes (Baier 
et al., 2000a; Rissanen et al., 2000; Elbein et al., 2001).  Association studies 
with HNF1β in Danish Caucasians (Ek et al., 2001) and Japanese (Babaya et 
al., 2001) have failed to find any relationship with type 2 diabetes.  A 
mutation in HNF4α has been associated with type 2 diabetes in Japanese 
subjects (Sakurai et al., 2000), however sequencing the entire coding region of 
HNF4α in Pima Indians failed to find any mutations associated with diabetes 
(Baier et al., 2000a).  Further studies are necessary to determine if HNF 
mutations are important in the pathophysiology of type 2 diabetes.  
 
The polymorphisms in the genes discussed above are unlikely to cause type 2 
diabetes.  However, many of these studies may not have used a sufficient 
number of subjects, limiting the statistical power to detect small effects.  
Alternatively genetic variations in the upstream promoter and enhancer 
regions of the genes may be associated with type 2 diabetes.  Given type 2 
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diabetes is a heterogeneous disease, subphenotyping may be necessary to 
detect the effects of genes with small effects.   
 
1.2.2 Identification of Novel Genes 
Identification of novel genes involved in the development of type 2 diabetes 
requires different strategies.  Gene discovery studies can be based on 
identifying gene mutations or differential gene expression. 
 
1.2.2.1 Whole Genome Scans 
Linkage studies identify Quantitative Trait Loci (QTL) when polymorphic 
markers co-segregates with a phenotype, such as type 2 diabetes, in two or 
more familial generations.  Whole genome scans utilise anonymous markers 
spread evenly throughout the entire genome.  Following the identification of a 
QTL, fine scale mapping and positional cloning strategies are used to identify 
the specific gene generating the linkage.  Genome wide scans with positional 
cloning are an expensive and time consuming gene discovery approach.  
Furthermore these studies are not well suited to detecting genes with small 
phenotypic effects in complex polygenic diseases such as type 2 diabetes 
(Elbein et al., 1994). 
 
Genome wide scans have identified loci associated with phenotypes related to 
type 2 diabetes in various populations, including Mexican Americans (Hanis 
et al., 1996; Duggirala et al., 1999; Mitchell et al., 2000), Finns from the 
isolated Botnia region (Mahtani et al., 1996; Parker et al., 2001), Pima Indians 
(Hanson et al., 1998), Utah Caucasians (Elbein et al., 1999), Canadian Oji-
Cree (Hegele et al., 1999), Ashkenazi Jews (Permutt et al., 2001) and Chinese 
Han (Luo et al., 2001).  The identification of the specific genes generating the 
linkage within these loci is continuing.   
 
The whole genome scan in Mexican Americans identified the 2q37.3 locus, 
referred to as NIDDM1 (Hanis et al., 1996).  NIDDM1 interacts with a gene on 
chromosome 15 to increase susceptibility to type 2 diabetes (Cox et al., 1999).  
Positional cloning has identified the calpain-10 gene within the NIDDM1 
locus, and identified polymorphisms within this gene that are associated with 
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type 2 diabetes (Horikawa et al., 2000).  Haplotypes of polymorphisms within 
calpain-10 contribute to the development of type 2 diabetes in Mexican 
Americans, and to a lesser extent in Germans and Finns from Botnia 
(Horikawa et al., 2000).   
 
Calpains are calcium dependent processing proteases implicated in various 
processes including intracellular signaling, proliferation and differentiation 
(Carafoli and Molinari, 1998) and may be involved in the insulin induced 
downregulation of IRS-1 (Smith et al., 1996).  Calpain-10 is expressed in liver 
as well as pancreatic islets and muscle.  A calpain10 polymorphism has been 
associated with decreased mRNA levels in skeletal muscle and insulin 
resistance in nondiabetic subjects (Baier et al., 2000b).  Genetic variation in 
calpain-10 was associated with hyperglycemia and reduced insulin secretion in 
a British population (Lynn et al., 2002).  Exposure of mouse pancreatic islets 
to calpain inhibitors for 4 hours enhanced glucose induced insulin secretion 
(Sreenan et al., 2001).  Exposure of isolated muscle strips to these inhibitors 
reduced insulin stimulated glucose uptake and glycogen synthesis and also 
reduced insulin stimulated glucose uptake in adipocytes (Sreenan et al., 2001).  
Continuing research is necessary to determine the precise physiological role of 
calpain-10 in the pathophysiology of type 2 diabetes. 
 
1.2.2.2 Gene Expression Approaches 
Another gene discovery approach is to examine the expression of a gene, 
rather than genetic mutations, for an association with a phenotype.  Gene 
expression approaches rely on the tight connection between the function of a 
gene product and its expression profile.  Generally each gene is expressed in 
the specific cell and under the specific conditions in which its product makes a 
contribution to fitness/cellular function (Brown and Botstein, 1999).   
 
The thousands of genes that are expressed within a tissue of interest at any 
given time limit the efficacy of gene expression studies to identify genes 
associated with a disease phenotype.  Oligonucleotide and cDNA microarray 
techniques can be used to simultaneously examine the expression of thousands  
ofgenes.  Importantly, generating cDNA from RNA does not require previous 
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knowledge of the cDNA sequence.  Furthermore, cDNA can be species and 
tissue specific and environmental conditions can be manipulated.  
 
The rapid advancement of this technology means that microarray is a cost and 
labour effective approach for gene expression profiling and gene discovery in 
complex diseases such as obesity and type 2 diabetes. 
 
1.2.2.2.1 cDNA Microarray 
Microarray protocols vary between laboratories.  A simplified protocol is 
shown schematically in Figure 1.3 and described below (Duggan et al., 1999). 
Templates for genes of interest are obtained from purposely, or randomly, 
selected clones of interest and amplified by PCR.  Following purification and 
quality control, aliquots are printed on coated glass microscope slides using a 
computer controlled robotic arrayer.  RNA from the sample of interest and 
also a reference are fluorescently labeled with Cy3- or Cy5-dUTP, 
respectively, during reverse transcription.  The labeled cDNA are combined 
and purified and allowed to hybridise to the clones of interest on the array.  
Laser excitation of the incorporated targets yield an emission with a 
characteristic spectra, which is measured using a scanning confocal 
microscope.  Monochrome images from the scanner are imported into 
software, merged, and a false colour image generated.   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.  Schematic diagram of the cDNA microarray procedure (Duggan 
et al., 1999). 
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Data from an experiment is viewed as the ratio of Cy3/Cy5.  A clone 
producing a ratio of 1 is equally expressed in the sample of interest and the 
reference sample.  Ratios >1 and <1 represent clones overexpressed and 
underexpressed in the sample respectively.   Gene expression information for 
each clone can be compiled from many RNA samples in many experimental 
conditions, including diabetic and nondiabetic. 
 
The ability of cDNA microarray to efficiently screen a randomly selected 
library of clones and identify genes that are differentially expressed with a 
phenotype is limited by the abundance of undesirable clones These include; 
clones only containing poly (A) mRNA tails, clones with very short cDNA 
inserts, clones only containing the 3’ half of the oligo(dT) primer used to 
synthesis cDNA, chimeric clones (different mRNAs artificially joined during 
ligation) (Bonaldo et al., 1996).    Furthermore, highly abundant mRNA 
transcripts inhibit the identification of low copy number mRNAs.  Three 
classes of mRNA transcripts have been identified based on their frequency 
within somatic cells; superprevalent (10-15 mRNAs that represent 10-20% of 
mRNA mass), intermediate (1000-2000 mRNAs, 40-45%) and complex 
(15,000-20,000 mRNAs, 40-45%) (Bonaldo et al., 1996).  Normalisation and 
subtraction approaches have been developed to increase the efficiency of 
identifying complex mRNAs. 
 
Normalisation reduces the frequency of all clones within a narrow range.  
Normalising, therefore avoids the repetitive identification of the same 
superprevalent cDNAs (Bonaldo et al., 1996).  Subtraction approaches can 
subsequently remove previously identified cDNA, or alternatively enrich for 
yet to be identified cDNAs.  Subtraction approaches, therefore increase the 
likelihood of identifying new cDNA’s (Bonaldo et al., 1996).   Normalisation 
and subtraction of cDNA libraries can dramatically improve the efficiency of 
cDNA microarray screening. 
 
1.2.2.2.2 Suppression Subtractive Hybridisation 
Suppression subtractive hybridisation (SSH) compares two cDNA 
populations, enriching for genes that are overexpressed in one of the 
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populations (Lisitsyn and Wigler, 1993; Diatchenko et al., 1996).  
Differentially expressed genes can be cloned and identified with cDNA 
microarray or traditional approaches such as cDNA dot blots.  Several obesity 
and diabetes genes have been identified using SSH, including resistin (Steppan 
et al., 2001) and adipogene (Larose et al., 2001). 
 
1.3 ANIMAL MODELS OF TYPE 2 DIABETES  
Although humans are the best models in which to explore the pathophysiology 
of type 2 diabetes, the invasive nature of many experiments has limited their 
usage.   Animal models of type 2 diabetes have been explored to further our 
understanding of this disease.   
 
1.3.1 Monogenic Animal Models 
Several animal models have been identified with single gene mutations that 
cause both obesity and type 2 diabetes.  Studies of these animals have led to 
significant advances in our understanding of the pathogenesis of these 
diseases. 
 
1.3.1.1 Obese Mouse  
An autosomal recessive mutation with full penetrance in the obese (ob/ob) 
mouse produces a phenotype characterised by infertility, severe obesity, 
hyperphagia, hyperinsulinemia and insulin resistance (Coleman, 1978).  
Hyperglycemia develops, although the severity depends on the background 
strain of the animal.  When the ob mutation is expressed in the C57BL/6J 
mouse diabetes is mild, due to compensatory hyperinsulinemia (Coleman and 
Hummel, 1973).  Severe diabetes occurs when the ob mutation is expressed in 
C57BL/KsJ mice, due to β-cell failure and insulin deficiency (Coleman and 
Hummel, 1967).   
 
The ob gene encodes the adipocyte secreted protein leptin.  Two mutations 
have been described in the ob gene resulting in either a truncated protein or 
complete absence of leptin (Zhang et al., 1994).  Obese mice display 
hyperphagia and reduced energy expenditure relative to controls.  
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Administration of leptin reduced food intake and increased energy expenditure 
and increased fat oxidation resulting in substantial weight loss in ob/ob mouse 
(Campfield et al., 1995; Pelleymounter et al., 1995; Halaas et al., 1997; Hwa 
et al., 1997). 
 
1.3.1.2 Diabetes Mouse  
The diabetic (db/db) mouse has an autosomal recessive mutation with full 
penetrance, which produces a phenotype identical to the obese mouse when 
these mutations are expressed on the same background strain (Coleman, 
1978).  The db mutation therefore produces severe diabetes when expressed in 
the C57BL/KsJ mouse (Coleman, 1978).   
 
The db gene was identified as the leptin receptor (OB-R) (Tartaglia et al., 
1995).  The db mutation causes abnormal splicing of the leptin receptor and 
inhibits leptin signal transduction (Lee et al., 1996).  Therefore, the phenotype 
of the obese and diabetic mice is due to leptin deficiency and leptin resistance 
respectively. 
 
1.3.1.3 Zucker Rat 
The Zucker (fa/fa) rat has an autosomal recessive mutationin the leptin 
receptor gene (Chua et al., 1996a).  The fa mutation is different to the db 
mutation (Chua et al., 1996b), although it produces a similar phenotype to the 
obese and diabetic mice including the early development of obesity, 
hyperphagia, hyperinsulinemia and insulin resistance, and mild hyperglycemia 
(Zucker, 1965; Zucker and Antoniades, 1972).   
 
Continuous inbreeding of fa/fa rats with the highest plasma glucose has led to 
the diabetic ZDF/drt-fa rat.  These rats are less obese and have lower plasma 
insulin than the original strain and more severe hyperglycemia that occurs in 
male rats only (Friedman et al., 1991).  The development of hyperglycemia in 
these rats is accompanied by reduced glucose oxidation (Etgen and Oldham, 
2000). 
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Expressing the fa mutation in the Wistar Koyoto rat (WKY/NDrt-fa) also 
produces a diabetic phenotype in male rats similar to the ZDF/drt-fa rat 
(Sugiyama et al., 1989b).  Female WKY/NDrt-fa rats can become diabetic 
with dietary intervention (Sugiyama et al., 1989a).  
 
1.3.1.4 KK Mouse 
The KK mouse develops moderate obesity, hyperinsulinemia and moderate 
hyperglycemia when fed a high energy diet (Ikeda, 1994).  Hyperglycaemia is 
more prominent in males (Shafrir, 1992).  The obesity and diabetes was 
thought to be polygenic in nature, but is now considered the result of a 
dominant gene with low penetrance (25%) (Butler and Gerritsen, 1970).   
 
Crossing the KK mouse with the yellow agouti mouse (Ay), a monogenic 
obese mouse with moderate hyperglycemia developed the KKAy mouse.  The 
KKAy mouse has more severe hyperglycemia and diabetes than the KK mouse 
(Iwatsuka et al., 1970). 
 
1.3.1.5 Otsuka Long-Evans Tokushima Fatty Rat 
The Otsuka Long-Evans Tokushima Fatty (OLETF) rat is an inbred rat strain 
with hyperphagia, obesity, increased visceral adiposity, hyperinsulinemia, 
insulin resistance and hyperglycemia when compared to the Long-Evans 
Tokushima Otsuka (LETO) strain (Kawano et al., 1992; Ishida et al., 1995).  
The OTLEF rat develops late onset diabetes at approximately 18-25 weeks of 
age.  Pancreatic β-cell failure and insulin deficiency occurs after the age of 40 
weeks (Kawano et al., 1992).  Postabsorptive EGP is elevated in diabetic and 
pre diabetic OLETF rats (Shiba et al., 1998).  
 
Relative to control animals, OLETF rats have significantly reduced energy 
expenditure relative to body weight, and slightly elevated fat oxidation 
(Ichikawa et al., 2000).  Energy expenditure profiles in young (8 week old) 
normoglycemic OLETF and control rats demonstrate a diurnal variation with 
reduced expenditure in the light phase.  The diurnal variation is abolished 
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following the development of hyperglycemia in OLETF rats (24 week old) 
(Ichikawa et al., 1998). 
 
The OLETF rat has also been proposed as a polygenic animal model, however 
these rats were found to lack the cholecystokinin (CCK)-A receptor due a 
genetic abnormality (Funakoshi et al., 1994).  The disrupted CCK-A gene 
induces hyperphagia in OLETF rats, contributing to the development of 
obesity and diabetes (Miyasaka et al., 1994). 
 
1.3.2 Polygenic Animal Models 
Type 2 diabetes in humans is a polygenic disease.  Therefore, polygenic 
animal models more closely resemble the human condition and are 
advantageous for gene discovery purposes.  Several polygenic animal models 
develop both obesity and type 2 diabetes. 
 
1.3.2.1 New Zealand Obese Mouse  
The New Zealand Obese (NZO) mouse is an inbred mouse strain that develops 
an early onset moderate obesity, increased visceral adiposity, hyperphagia, 
hyperleptinemia, hyperinsulinemia, and moderate hyperglycemia (Veroni et 
al., 1991).  NZO mice have increased EGP from an early age (Veroni et al., 
1991).  
 
The NZO mouse may be a polygenic animal model although this is yet to be 
demonstrated.  Given this strain is inbred, the metabolic abnormalities in the 
NZO mouse may be the result of a major gene with low penetrance similar to 
the KK mouse.  NZO mouse are insensitive to peripheral leptin administration 
despite being sensitive to centrally administered leptin, suggesting a defect in 
leptin transport into the brain may contribute to the obesity in this animal 
(Halaas et al., 1995).  
 
1.3.2.2 Macaca mulatta (Rhesus Monkey) 
Obesity develops in approximately 50 percent of rhesus monkeys in captivity 
with ad libitum access to food, and body fat is predominantly stored centrally 
(Hansen and Bodkin, 1993).  Food intake does not vary greatly between 
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animals suggesting differences in energy expenditure or substrate utilisation 
may contribute to the development of obesity (Hansen and Bodkin, 1993).   
 
Many obese rhesus monkeys develop diabetes after maturity, between the ages 
of 15 and 21, although some monkeys remain normoglycemic (Hansen and 
Bodkin, 1986).  Diabetes is accompanied by polydipsia, polyuria, glycosuria, 
polyphagia and eventual weight loss, similar to humans (Hansen and Bodkin, 
1986).  
 
A six year longitudinal study found that approximately 30 percent of obese 
adult rhesus monkeys developed overt type 2 diabetes, and a further 50 
percent progressively developed impaired glucose tolerance, suggesting that 
they may eventually become diabetic (Hansen and Bodkin, 1986).  The 
phenotypic heterogeneity in these monkeys as they develop impaired glucose 
tolerance resembles that seen in humans.  Pre diabetic rhesus monkeys 
displayed elevated fasting insulin levels and increased glucose stimulated 
insulin secretion (Hansen and Bodkin, 1986).  Increased EGP develops in 
parallel with increased fasting plasma glucose (Bodkin et al., 1989). 
 
Long term (8.5 years) dietary energy restriction of rhesus monkeys to 70 
percent of their normal food intake, reduced fasting insulin and glucose 
stimulated insulin concentrations, and increased insulin sensitivity and glucose 
tolerance compared to control monkeys (Gresl et al., 2001).  Similarly, 
preventing the development of obesity in rhesus monkeys with a weight 
maintaining diet has been shown to improve glucose tolerance and insulin 
sensitivity and to prevent the development of hyperinsulinemia (Hansen and 
Bodkin, 1993). 
 
The physiological and genetic similarity between rhesus monkeys and 
humans, and the heterogeneous development of type 2 diabetes and obesity in 
these animals, suggest they would be an ideal animal model for the study of 
these diseases.  However, the use of rhesus monkeys is impractical given these 
are relatively large animals (up to 20kg), that typically live for 30 years and 
may remain normoglycemic for 20 years (Hansen and Bodkin, 1986; Hansen 
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and Bodkin, 1993).  Furthermore, primates are emotional and intelligent 
animals raising serious ethical issues. 
 
1.3.2.3 Psammomys obesus (Israeli Sand Rat) 
Psammomys obesus, commonly known as the Israeli sand rat, is an outbred 
animal model of obesity and type 2 diabetes.  P. obesus belong to the 
Gerbillanae family and are native to the deserts of North Africa and the 
Middle East (Shafrir and Gutman, 1993).  In their natural environment these 
animals survive on a diet of low energy salt bush (atriplex halimus).  To 
obtain sufficient energy these animals consume large quantities of salt bush, 
estimated to be up to 65 percent of their body weight (Pinshow, 1993).  P. 
obesus also have a relatively low BMR, estimated to be 60 percent of that 
expected for rodents of similar mass (Pinshow, 1993).  Neither obesity or 
diabetes have been reported in P. obesus in the wild (Shafrir and Gutman, 
1993).   
 
Early studies by (Hackel et al., 1966) found that maintaining P. obesus on an 
ad libitum diet of laboratory chow caused some animals to becoming severely 
glucose intolerant and hyperinsulinemic, and some also became 
hypoinsulinemic with ketoacidosis and died.  Conversely, some animals 
maintained glucose tolerance at the expense of hyperinsulinemia, while others 
were phenotypically unaffected.  Restricting the food intake of P. obesus to 30 
calories per day was shown to prevent glucose intolerance and diabetes 
(Hackel et al., 1967).   
 
The colony of P. obesus at the Geelong campus of Deakin University is 
maintained on a standard laboratory chow diet.  The distribution of body 
weight within this colony approximates a normal distribution and resembles 
that seen in human populations (Figure 1.4) (Walder et al., 2000).  A familial 
effect accounts for 51 percent of the variation in body weight (Walder et al., 
2000).   
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Cross sectional studies have demonstrated an inverted “U” shaped relationship 
between plasma glucose and insulin concentrations (Figure 1.5) (Barnett et al., 
1994a).  This closely resembles Starlings curve of the pancreas seen in 
humans (DeFronzo, 1988).  Longitudinal studies on the development of 
diabetes within P. obesus demonstrate a similar relationship between glucose 
and insulin concentrations (Barnett et al., 1994a).  A familial effect accounts 
for up to 26 percent of the variation in blood glucose and plasma insulin 
concentrations in these animals (Walder et al., 2000). 
Figure 1.4.  Frequency distribution of body weight in 16 week old P. obesus 
(Walder et al., 2000). 
 
Figure 1.5.  Plasma glucose and insulin concentrations in 19 week old P. 
obesus (Barnett et al., 1994a). 
 
Diabetic P. obesus display a range of metabolic abnormalities including 
hyperphagia, obesity, hyperinsulinemia and elevated plasma cholesterol and 
triglycerides (Barnett et al., 1995).  Fasting plasma glucose concentrations are 
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positively correlated with both hepatic glucose production and the metabolic 
clearance rate of glucose (Barnett et al., 1994a; Collier et al., 1997).  
Peripheral and hepatic insulin resistance precedes overt diabetes in P. obesus 
(Kalderon et al., 1986; Shafrir and Gutman, 1993).  EGP has been associated 
with increased glycogen synthase and PEPCK activity suggesting elevated 
gluconeogenesis and glycogenolysis (Barnett et al., 1995). Hepatic insulin 
resistance coincides with elevated hepatic triglyceride content (Zoltowska et 
al., 2001).   
 
P. obesus display the characteristics of a polygenic animal model of obesity 
and type 2 diabetes, and are therefore an ideal animal model for the study of 
these diseases.  Furthermore the heterogeneity of phenotypic responses seen in 
P. obesus upon consumption of a relatively high energy diet closely resemble 
that seen in various traditional human populations that have adopted a modern 
lifestyle including Pima Indians and Nauruans (Knowler et al., 1981; Zimmet 
et al., 1990).  These environmental changes are characterised by the 
consumption of energy dense foods with little physical activity and are 
thought to unmask a strong genetic predisposition to the development of 
obesity and type 2 diabetes (Zimmet et al., 1990).   
 
1.4 SUMMARY 
Type 2 diabetes mellitus is a metabolic disease characterised by defects in 
insulin secretion and insulin action, and disturbances in carbohydrate, fat and 
protein metabolism that result in hyperglycemia.  The liver contributes to the 
development of type 2 diabetes through reduced suppression of postprandial 
EGP and elevated postabsorptive EGP.  The aetiology of this disease includes 
a strong genetic component.  However, specific genes involved in the 
pathogenesis of type 2 diabetes remain elusive.  Gene discovery approaches 
based on gene expression can identify novel genes associated with this 
disease.  P. obesus is a unique polygenic animal model of obesity and type 2 
diabetes, displaying many metabolic abnormalities seen in humans.  However, 
it is unclear if disturbances in whole body energy metabolism and substrate 
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utilisation occur in theses animals.  These animals are ideally suited for studies 
aiming to identify genes associated with type 2 diabetes. 
 
1.5 AIMS 
Firstly, this study aimed to characterise whole body energy metabolism and 
substrate utilisation in P. obesus, to further validate these animals as an ideal 
model of obesity and type 2 diabetes.  Lean-NGT, obese-IGT and obese-
diabetic animals were examined with indirect calorimetry in several metabolic 
states including; fed, fasted and dietary energy restricted. 
 
Secondly, this study aimed to identify novel genes differentially expressed in 
the liver of lean-NGT and obese-diabetic P. obesus.  Suppression subtractive 
hybridisation was used to enrich a cDNA library for differentially expressed 
genes.  These genes were subsequently screened with cDNA dot blots and 
cDNA microarray to identify individual genes associated with type 2 diabetes. 
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Energy Metabolism in Psammomys obesus 
 
3.1 ABSTRACT 
Psammomys obesus is a polygenic animal model of obesity and type 2 
diabetes.  Three studies were conducted to characterise energy expenditure 
and substrate utilisation in lean-NGT, obese-IGT and obese-diabetic P. 
obesus.   
 
Experiment one examined P. obesus with ad libitum access to food.  Energy 
expenditure and fat oxidation were elevated in the obese-IGT and obese-
diabetic groups in proportion to body weight.  Glucose oxidation was not 
different between groups.  Obese-diabetic P. obesus displayed elevated 
nocturnal blood glucose levels and fat oxidation.   
 
Experiment two examined P. obesus following 14 days of dietary energy 
restriction.  Body weight was reduced and plasma insulin and blood glucose 
levels were normalised in all groups.  Glucose oxidation was reduced and fat 
oxidation was increased.  Following dietary energy restriction, energy 
expenditure, glucose oxidation and fat oxidation were not different between 
groups of P. obesus.   
 
Experiment three examined P. obesus after 24 hours of fasting.  Plasma insulin 
and blood glucose levels were normalised in all groups.  Energy expenditure 
and glucose oxidation were greatly reduced and fat oxidation was increased.  
Following fasting, energy expenditure, glucose oxidation and fat oxidation 
were not different between groups of P. obesus.   
 
Energy expenditure and whole body substrate utilisation in P. obesus was 
similar to that seen in humans, and these animals responded normally to 
fasting and dietary energy restriction.  Energy expenditure and fat oxidation 
were elevated in obese-IGT and obese-diabetic animals in proportion to body 
weight.  P. obesus respond normally to short term fasting and dietary energy 
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restriction.  Elevated nocturnal fat oxidation rates and plasma glucose levels in 
obese-diabetic P. obesus may be an important factor in the pathogenesis of 
obesity and type 2 diabetes in these animals.  These studies have provided 
further validation of P. obesus as an ideal animal model of obesity and type 2 
diabetes.   
 
3.2 INTRODUCTION 
The pathogenesis of obesity and type 2 diabetes are interrelated.  Obesity is 
the strongest determinant of type 2 diabetes with over 85 percent of type 2 
diabetic patients obese (WHO, 1994).  Obesity occurs as a result of a chronic 
imbalance between energy intake and expenditure.   
 
Obesity is associated with elevated energy expenditure however, relative to fat 
free mass energy expenditure is similar to lean controls (Bogardus et al., 
1986a; Nelson et al., 1992).  Longitudinal studies have shown that low relative 
energy expenditure is predictive of subsequent weight gain (Ravussin et al., 
1988).  Furthermore, a high respiratory quotient (RQ), indicative of a low ratio 
of fat to glucose oxidation, has also been shown to predict weight gain in some 
studies (Zurlo et al., 1990; Seidell et al., 1992).  Some studies with post-obese 
subjects have found reduced resting energy expenditure (Geissler et al., 1987; 
Weigle et al., 1988), and reduced fat oxidation (Larson et al., 1995; Wyatt et 
al., 1999; Weyer et al., 2000a), relative to weight matched controls suggesting 
a predisposition to weight gain in some subjects.   
 
Elevated basal metabolic rate (BMR) has been found in some type 2 diabetic 
subjects (Ravussin et al., 1983; Bogardus et al., 1986b; Fontvieille et al., 
1992; Franssila-Kallunki and Groop, 1992), possibly due to the energy cost of 
gluconeogenesis, which is elevated in type 2 diabetes (Franssila-Kallunki and 
Groop, 1992).  Whole body glucose oxidation rates have been negatively 
correlated with plasma glucose concentrations in type 2 diabetic subjects 
(Bogardus et al., 1984) and elevated whole body fat oxidation has also been 
found (Franssila-Kallunki and Groop, 1992).  However, other studies have 
found similar glucose and fat oxidation rates in diabetic subjects (Vaag et al., 
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1992; Fery et al., 1993; Kelley et al., 1994), suggesting hyperglycemia is 
unlikely to be due to reduced systemic glucose oxidation.   
 
Reducing dietary energy intake and increasing energy expenditure are the 
primary weight loss recommendations for obese patients, particularly those 
with type 2 diabetes (Franz et al., 2002).  Weight loss improves insulin 
sensitivity and glucose tolerance (Christiansen et al., 2000).  Caloric 
restriction and short term fasting also improve insulin sensitivity and glucose 
tolerance prior to any change in body weight, due to the reduced glucose 
intake and decreased endogenous glucose production (EGP) (Christiansen et 
al., 2000). 
 
Psammomys obesus is a unique polygenic animal model of obesity and type 2 
diabetes.  When housed in laboratory conditions with ad libitum access to 
standard rodent chow, some animals remain lean and healthy whereas others 
develop obesity and type 2 diabetes (Hackel et al., 1966; Barnett et al., 
1994a).   
 
The aim of the present study was to characterise whole body energy balance 
and substrate utilisation in lean-NGT, obese-IGT and obese-diabetic P. 
obesus, to further characterise P. obesus as an animal model of obesity and 
type 2 diabetes.  Energy metabolism will be examined using indirect 
calorimetry in animals with ad libitum access to food, as well as animals 
following a 24 hour fast and following 14 days of dietary energy restriction. 
 
3.3 RESEARCH DESIGN AND METHODS 
Research design and methods are discussed in detail in Chapter 2 and 
described briefly below.   
 
3.3.1 Characterisation of Energy Metabolism 
Characterisation of baseline energy metabolism in P. obesus was conducted 
with two separate experiments.  Experiment 1 utilised an Oxymax Equal Flow 
Indirect Calorimeter (Columbus Instrument, Ohio, USA) to measure fat 
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oxidation, carbohydrate oxidation, RQ and total energy expenditure (TEE) as 
described previously (Weir, 1990; Frayn, 1983).  Physical activity was 
measured while animals were in the calorimeter using the Opto-Varimax 
Mini-Infrared Animal Activity Monitoring System (Columbus Instruments, 
Ohio, USA).   
 
At 16 weeks of age lean-NGT (n=10), obese-IGT (n=10) and obese-diabetic 
(n=10) P. obesus were separated and daily food intake was measured for 14 
days.  At 18 weeks of age body weight was measured and animals underwent 
24 hours of indirect calorimetry.  Animals had ad libitum access to food and 
water.  Blood samples were collected for measurement of blood glucose with 
an enzymatic glucose analyser (Yellow Springs Instruments, Yellow Springs, 
USA) and plasma insulin (Insulin RIA, Phadeseph, Uppsala, Sweden). 
 
Experiment 2 examined the diurnal influence on energy metabolism in another 
group of P. obesus.  At 16 weeks of age lean-NGT (n=8), obese-IGT (n=8) 
and obese-diabetic (n=8) P. obesus were separated and daily food intake was 
measured for 14 days.  At 18 weeks of age, blood samples were collected 
every 6 hours over a 24 hour period.  Animals had ad libitum access to food 
and water.  Blood glucose concentrations were measured, as were plasma 
insulin, cortisol (Orion Diagnostica, Finland), leptin (Linco Research Inc, St 
Charles, USA) and FFA (Free Fatty Acids Half-micro Test, Roche 
Diagnostics, Mannheim, Germany).   
 
3.3.2 Dietary Energy Restriction 
Energy metabolism was characterised in P. obesus before and after dietary 
energy restriction.  At 16 weeks of age lean-NGT (n=13), obese-IGT (n=15) 
and obese-diabetic (n=12) P. obesus were separated and daily food intake was 
measured for 14 days.  At 18 weeks of age body weight was measured, blood 
samples were collected and animals underwent 24 hours of indirect 
calorimetry.  Animals had ad libitum access to food and water.   
 
Animals were separated into control and restricted groups for a 14 day 
experimental period.  Groups were matched for sex, age and body weight.  
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Control animals had ad libitum access to food, whereas restricted animals 
were given 66 percent of the average food intake of their respective group 
during the baseline period.  Body weight and food disappearance were 
measured daily.  At the completion of the restriction period blood samples 
were taken and animals were placed in the indirect calorimeter for another 24 
hours.   
 
3.3.3 Fasting 
Energy metabolism was characterised in P. obesus while fasting.  Lean-NGT 
(n=5), obese-IGT (n=5) and obese-diabetic (n=5) 18-week old P. obesus were 
placed in an indirect calorimeter for 48 hours.  Animals were allowed ad 
libitum access to food for the first 24 hours and then fasted for the remaining 
24 hours.  Blood samples were collected at 0, 24 and 48 hours from the 
beginning of the calorimetry period for measurement of blood glucose and 
plasma insulin. 
 
3.3.4 Statistical Analyses 
Statistical analyses were conducted using SPSS (Version 10, SPSS inc, 
Chicago, USA).  A Kolmogorov-Smirnov test was used to examine the 
distribution of data.  Normally distributed data were analysed using an 
independent samples T test or paired samples T test.  One way ANOVA was 
used with the LSD post hoc test when variance between groups was 
homogeneous, and with the Games-Howell post hoc test when variances were 
not homogenous.  Non-normally distributed data was analysed using a Mann-
Whitney test.  The relationship between linear variables was assessed using 
Pearson and Spearman correlations for normally and non-normally distributed 
data respectively.  Total energy expenditure was adjusted for differences in 
body weight using linear regression as previously described (Ravussin and 
Bogardus, 1989).  Statistical significance was set at p<0.05.   
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3.4 RESULTS 
3.4.1 Characterisation of Energy Metabolism 
Baseline energy metabolism was examined in lean-NGT, obese-IGT and 
obese-diabetic P. obesus.  Phenotypic and metabolic data for these animals is 
shown in Table 3.1.  Relative to lean-NGT animals, obese-IGT animals were 
hyperinsulinemic, and obese-diabetic animals were hyperinsulinemic and 
hyperglycaemic.  Obese-diabetic P. obesus consumed more food than lean-
NGT animals, although this did not reach statistical significance (p=0.065).  
 
Table 3.1 Phenotypic and metabolic characteristics of P. obesus. TEE = total 
energy expenditure, RQ = respiratory quotient, CHO = carbohydrate.  * 
Significantly different to lean-NGT (p<0.05). 
 
 Lean-NGT Obese-IGT Obese-Diabetic 
Body Weight 
(g) 
211 + 0.4 249 + 7* 240 + 5* 
Plasma Insulin 
(mU/l) 
57 + 18 379 + 190* 531 + 101* 
Blood Glucose 
(mmol/l) 
3.8 + 0.2 4.1 + 0.4 16.0 + 1.0* 
Food Intake 
(g) 
12.7 + 0.4 13.0 + 0.9 14.5 + 1.0 
TEE 
(kJ/day) 
104 + 6 139 + 22* 133 + 5* 
RQ 
(ratio) 
0.88 + 0.01 0.86 + 0.01 0.85 + 0.01 
CHO Oxidation 
(mg/min) 
2.2 + 0.2 2.5 + 0.2 2.2 + 0.3 
Fat Oxidation 
(mg/min) 
0.4 + 0.1 0.7 + 0.1* 0.8 + 0.1* 
Activity 
(counts) 
189 + 19 245 + 38 260 + 25 
 
TEE was elevated in obese-IGT and obese-diabetic P. obesus relative to lean-
NGT animals (p<0.05, Table 3.1).  TEE was positively correlated with body 
weight (r2=0.304, p<0.001, Figure 3.1), and after correction for body weight, 
TEE was not different between groups.  Physical activity levels were not 
different between groups. 
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Figure 3.1 Linear correlation between total energy expenditure and body 
weight in P. obesus (r2=0.304, p<0.001). 
 
Mean RQ tended to be lower in obese-diabetic P. obesus relative to lean-NGT 
animals (p=0.075), indicative of elevated fat oxidation relative to glucose 
oxidation (Table 3.1).  Analysis of the 24 hour RQ profile revealed significant 
diurnal variation in obese-diabetic P. obesus with a peak at 1500 hours and a 
nadir at 0100 hours (Figure 3.2).   
 
The mean fat oxidation rate was significantly elevated in obese-IGT and 
obese-diabetic P. obesus relative to lean-NGT animals (p<0.05, Table 3.1).  
Fat oxidation was positively correlated with body weight (r2=0.187, p<0.05, 
Figure 3.3) and relative to body weight, fat oxidation rates were not different 
between groups.  Analysis of the 24 hour fat oxidation profile revealed 
significant diurnal variation in obese-diabetic P. obesus with a peak at 0100 
hours and a nadir at 1500 hours (Figure 3.4a).  Plasma FFA levels in obese-
diabetic animals also exhibited a peak at 0600 hours (p<0.05, Figure 3.4b).  
Lean-NGT and obese-IGT P. obesus did not exhibit any diurnal variation in 
fat oxidation and plasma FFA levels. 
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Figure 3.2 24 hour respiratory quotient profile in P. obesus.  Data expressed 
as mean +SEM.  * Significantly different to obese-IGT and obese-diabetic 
(p<0.05).  # Significantly different to lean-NGT and obese-IGT (p<0.05).   
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Figure 3.3 Linear correlation between fat oxidation and bodyweight in P. 
obesus (r2=0.187, p<0.05). 
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Figure 3.4 24 hour fat oxidation (3.4a) and plasma free fatty acid (3.4b) 
profiles in P. obesus.  Data expressed as mean +SEM.  * Significantly 
different to obese-IGT and obese-diabetic (P<0.05).  # Significantly different 
to obese-IGT (P<0.05). ^ Significantly different to lean-NGT (P<0.05). 
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The mean carbohydrate oxidation rates were not different between groups 
(Table 3.1).  Analysis of the 24 hour glucose oxidation profile revealed a 
significant reduction in obese-diabetic animals between 2300-0700 hours, with 
a nadir at 0100 hours and a peak at 1300 hours (Figure 3.5a).  Blood glucose 
levels were significantly diurnally elevated at 2400 hours in obese-diabetic P. 
obesus (p<0.05, Figure 3.5b), and tended to be elevated in lean-NGT and 
obese-diabetic animals.   
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Figure 3.5 24 hour glucose oxidation (3.5a) and blood glucose (3.5b) profiles 
in P. obesus.  Data expressed as mean +SEM.  * Significantly different lean-
NGT (P<0.05).  # Significantly different to obese-IGT (P<0.05). 
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The 24 hour profile for plasma leptin concentrations in lean animals displayed 
a nocturnal increase with a peak between 1800-2400 hours and a nadir at 0600 
hours (Figure 3.6).  Obese-IGT and obese-diabetic groups did not display this 
diurnal variation in leptin concentrations.  No diurnal variations were observed 
in activity levels, food intake or plasma insulin and cortisol concentrations in 
P. obesus.  
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Figure 3.6 24 hour plasma leptin profiles in P. obesus.  Data expressed as 
mean +SEM.  * Significantly different to obese-IGT and obese-diabetic 
(P<0.05). 
 
3.4.2 Dietary Energy Restriction 
The effect of dietary energy restriction on energy metabolism was examined in 
lean-NGT, obese-IGT and obese-diabetic P. obesus.  Two cohorts of animals 
were used.  One group was placed on a diet restricting energy intake 
(restricted) and the other group was allowed ad libitum access to food 
(control).  Phenotypic data for the restricted and control animals measured 
prior to restriction (age 18 weeks) and following restriction (age 20 weeks) are 
shown in Table 3.2.  Phenotypic data for the control animals, measured at 18 
weeks and 20 weeks are shown in Table 3.3.  Body weight was significantly 
reduced in all restricted groups (p<0.05).  Restriction significantly reduced 
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blood glucose and plasma insulin concentrations (p<0.05) in all groups.  
Following energy restriction, blood glucose and plasma insulin concentrations 
were not significantly different between lean-NGT, obese-IGT and obese-
diabetic P. obesus.  Amongst control animals body weight, blood glucose and 
plasma insulin concentrations did not significantly change over the 
experimental period. 
 
Table 3.2 Phenotypic and metabolic data for restricted P. obesus before and 
after the dietary energy restriction period.  TEE = total energy expenditure, 
RQ = respiratory quotient, CHO = carbohydrate. * Significantly different to 
lean-NGT (p<0.05).   # Significantly different to pre restriction (p<0.05). 
 
Lean-NGT Obese-IGT Obese-Diabetic  
Pre Post Pre Post Pre Post 
Body Weight 
(g) 
229 
+ 7 
212 
+ 6# 
234 
+ 5 
206 
+ 11# 
260 
+ 5* 
237 
+ 4# 
Plasma Insulin 
(mU/l) 
67  
+ 13 
60 
+ 15 
439 
+ 109* 
42 
+ 9# 
486 
+ 140* 
60 
+ 17# 
Blood Glucose 
(mmol/l) 
3.7 
+ 0.2 
4.3  
+ 0.3 
4.4 
+ 0.6 
4.3 
+ 0.4 
15.6 
+ 1.7 
4.7 
+ 0.5# 
TEE 
(kJ/day) 
120 
+ 7 
115 
+ 7 
127 
+ 18 
115 
+ 5 
140 
+ 9* 
127 
+ 7* 
RQ 
(ratio) 
0.87 
+ 0.01  
0.82 
+ 0.01# 
0.86 
+ 0.02 
0.82  
+ 0.01# 
0.82 
+ 0.01* 
0.81 
+ 0.01# 
CHO Oxidation 
(mg/min) 
2.3 
+ 0.2 
1.6 
+ 0.2# 
2.3 
+ 0.3 
1.7 
+ 0.2# 
2.4 
+ 0.4 
1.6 
+ 0.1# 
Fat Oxidation 
(mg/min) 
0.67 
+ 0.11 
0.86 
+ 0.08# 
0.61 
+ 0.2 
0.86 
+ 0.06# 
0.81 
+ 0.12* 
1.0 
+ 0.1 
Activity 
(counts) 
193 
+ 32 
277 
+ 76 
249 
+ 32 
289 
+ 46 
214 
+ 26 
246 
+ 95 
 
Indirect calorimetry and physical activity data, measured prior to and 
following dietary energy restriction, for the restricted and control groups are 
shown in Tables 3.2 and 3.3 respectively.  Following energy restriction, TEE 
was reduced in all groups although this did not reach statistical significance.  
The change in body weight was positively correlated with the change in TEE 
(r2=0.150, p<0.05, data not shown), and TEE remained proportional to body 
weight in all three groups (data not shown).  Activity levels were not 
significantly affected by energy restriction.  Amongst control animals TEE did 
not significantly change over the 2 week period. 
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Table 3.3 Phenotypic and metabolic data for control P. obesus before and 
after the dietary energy restriction period.  TEE = total energy expenditure, 
RQ = respiratory quotient, CHO = carbohydrate.  * Significantly different to 
lean-NGT (p<0.05).   
 
Lean-NGT Obese-IGT Obese-Diabetic  
Pre Post Pre Post Pre Post 
Body Weight 
(g) 
228 
+ 8 
232 
+ 8 
234 
+ 5 
241 
+ 5 
257 
+ 6* 
260 
+ 5* 
Plasma Insulin 
(mU/l) 
81 
+ 14 
79 
+ 19 
313 
+ 25* 
280 
+ 64* 
413 
+ 88* 
309 
+ 49* 
Blood Glucose 
(mmol/l) 
3.9 
+ 0.2 
4.6 
+ 0.6 
4.4 
+ 0.4 
4.2 
+ 0.5 
13.0 
+ 1.2* 
13.7 
+ 1.9* 
TEE 
(kJ/day) 
109 
+ 12 
109 
+ 9 
115 
+ 7 
121 
+ 7 
145 
+ 8* 
136 
+ 7* 
RQ 
(ratio) 
0.86  
+ 0.01 
0.86 
+ 0.01 
0.85 
+ 0.01 
0.87 
+ 0.01 
0.82 
+ 0.01* 
0.83 
+ 0.01* 
CHO Oxidation 
(mg/min) 
2.1 
+ 0.1 
1.9 
+ 0.2 
2.1 
+ 0.2 
1.9 
+ 0.2 
2.2 
+ 0.3 
1.9 
+ 0.2 
Fat Oxidation 
(mg/min) 
0.53 
+ 0.11 
0.54 
+ 0.01 
0.59 
+ 0.08 
0.57 
+ 0.01 
0.95 
+ 0.12* 
0.90 
+ 0.10* 
Activity 
(counts) 
178 
+ 40 
180 
+ 26 
180 
+ 27 
215 
+ 22 
211 
+ 29 
237 
+ 18 
 
RQ was significantly reduced with dietary energy restriction in lean-NGT, 
obese-IGT and obese-diabetic P. obesus (p<0.05).  Glucose oxidation was 
significantly reduced in all restricted groups (p<0.05), and fat oxidation was 
increased in all groups, although this did not reach statistical significance in 
obese-diabetic animals (Table 3.2).  Following energy restriction RQ, glucose 
oxidation and fat oxidation were not significantly different between the three 
groups.  Amongst control animals RQ, fat oxidation and glucose oxidation 
rates did not significantly change over the 2 week period. 
 
3.4.3 Fasting 
The effect of 24 hour fasting on metabolism was also examined in P. obesus.  
Phenotypic data from lean-NGT, obese-IGT and obese-diabetic animals, prior 
to and following fasting is shown in Table 3.4.  Fasting significantly reduced 
plasma insulin concentrations in obese-IGT and obese-diabetic P. obesus 
(p<0.05).  Fasting significantly reduced blood glucose concentrations in 
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obese-diabetic P. obesus (p<0.05).  Following fasting, blood glucose and 
plasma insulin concentrations were not significantly different between groups.   
 
Table 3.4 Phenotypic and metabolic data for P. obesus before and after the 
fasting period.  TEE = total energy expenditure, RQ = respiratory quotient, 
CHO = carbohydrate.  * Significantly different to lean-NGT (p<0.05).  # 
Significantly different to fed (p<0.05). 
 
Lean-NGT Obese-IGT Obese-Diabetic  
Fed Fast Fed Fast Fed Fast 
Body Weight 
(g) 
229 
+ 15 
225 
+ 16 
249 
+ 5 
243 
+ 6 
258 
+ 9 
253 
+ 9 
Plasma Insulin 
(mU/l) 
64 
+ 25 
47 
+ 15 
284 
+ 77* 
78 
+ 19# 
465 
+ 176* 
45 
+ 11# 
Blood Glucose 
(mmol/l) 
3.9 
+ 0.5 
3.9 
+ 0.3 
3.8 
+ 0.4 
4.3 
+ 0.3 
13.7 
+ 1.9* 
5.3 
+ 0.8# 
TEE 
(kJ/day) 
114 
+ 6 
97 
+ 2# 
127 
+ 6 
103 
+ 7# 
128 
+ 6 
100 
+ 9# 
RQ 
(ratio) 
0.86 
+ 0.01 
0.75 
+ 0.02# 
0.84 
+ 0.01 
0.71 
+ 0.02# 
0.81 
+ 0.01 
0.74 
+ 0.01# 
CHO Oxidation 
(mg/min) 
2.0 
+ 0.1 
0.70 
+ 0.01# 
1.7 
+ 0.2 
0.60 
+ 0.01# 
1.7 
+ 0.4 
0.60 
+ 0.03# 
Fat Oxidation 
(mg/min) 
0.70 
+ 0.01 
0.93 
+ 0.01# 
0.85 
+ 0.02 
1.10 
+ 0.01# 
0.95 
+ 0.01 
1.10 
+ 0.01 
Activity 
(counts) 
221 
+ 52 
202 
+ 24 
212 
+ 17 
230 
+ 16 
219 
+ 17 
188 
+ 43 
 
Indirect calorimetry and physical activity data for the 24 hour baseline period 
and the 24 hours while the animals were fasting are shown in Table 3.4.  Mean 
fasting TEE was significantly lower than baseline in lean-NGT, obese-IGT 
and obese-diabetic P. obesus (p<0.05).  Mean fasting TEE was not 
significantly different between groups.  Activity levels were not significantly 
affected by fasting. 
 
RQ was significantly reduced in lean-NGT, obese-IGT and obese-diabetic P. 
obesus (p<0.05).  Glucose oxidation was significantly reduced in all groups 
(p<0.05), and fat oxidation was increased, although this did not reach 
statistical significance in the obese-diabetic animals (Table 3.4).  Following 
fasting, RQ, glucose oxidation and fat oxidation were not significantly 
different between groups. 
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3.5 DISCUSSION 
3.5.1 Energy Intake and Expenditure in Psammomys obesus 
Obesity in P. obesus is accompanied by an elevation in energy expenditure, 
independently of the presence of diabetes.  However, energy expenditure 
remains proportional to body weight in lean-NGT, obese-IGT and obese-
diabetic animals, suggesting obesity is unlikely to be the result of a gross 
disturbance in energy expenditure.  Food intake was not significantly different 
between lean and obese groups, although there was a tendency for increased 
intake in obese-diabetic animals.  Studies in humans have shown energy 
expenditure, relative to FFM, is not different between lean and obese subjects 
supporting the findings of this study (Bogardus et al., 1986a; Nelson et al., 
1992).   
 
Dietary energy restriction reduced body weight in all animals.  Energy 
expenditure was subsequently reduced in proportion to the reduction in body 
weight, and relative to body weight, energy expenditure was not different 
between groups.  Energy expenditure was dramatically reduced with fasting 
and this response was not different between groups.  Taken together these 
results suggest that obese P. obesus do not manifest a gross inability to 
regulate energy expenditure in response to dietary manipulations.  A 
significant increase in energy intake accompanying obesity in P. obesus was 
expected, however estimating food intake from food disappearance data may 
not have been accurate enough to detect these differences.  A study with 
inbred diabetes prone and diabetes resistant lines of P. obesus found the 
energy cost of weight gain was lower in the diabetes prone line suggesting 
differences in either tissue content or energy expenditure (Kalman et al., 
1993).  Longitudinal energy metabolism studies in pre-obese P. obesus are 
necessary to determine the primary cause of obesity in our outbred colony. 
 
The reduction in energy expenditure accompanying dietary energy restriction 
is a survival mechanism that compensates for periods of famine (Weigle et al., 
1988).  The magnitude of the reduction in energy expenditure in P. obesus was 
less than that seen in other rodents (Hill et al., 1985).  Baseline energy 
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expenditure in P. obesus is only 60 percent of that seen in rodents of similar 
mass (Pinshow, 1993), suggesting these animals have little room left for 
further energy conservation. 
 
In the present study individual components of energy expenditure (BMR, 
thermogenesis and physical activity) were not measured directly.  However, 
physical activity, measured as the number of infrared beams broken, was not 
different following dietary restriction.  Studies in rhesus monkeys (Kemnitz et 
al., 1993) and humans (Weyer et al., 2000b) have found reduced physical 
activity following dietary energy restriction.  Although speculative, the 
maintenance of physical activity levels in P. obesus may be an adaptive 
response to search for food.  The most likely cause of the decreased energy 
expenditure accompanying dietary energy restriction is a reduction in BMR 
due to the decrease in body weight, however a reduction in thermogenesis is 
also possible.  
  
3.5.2 Substrate Utilisation in Psammomys obesus 
Whole body glucose oxidation rates were not different between lean-NGT, 
obese-IGT and obese-diabetic P. obesus.  Furthermore, whole body glucose 
oxidation rates following dietary energy restriction and while fasting were not 
different between groups.  Hyperglycemia is therefore unlikely to be due a 
defect in whole body glucose oxidation.   Similarly, studies in humans have 
shown fasting whole body glucose oxidation rates were not different between 
type 2 diabetic subjects and controls (Vaag et al., 1992; Fery et al., 1993; 
Kelley et al., 1994).  
 
Fat oxidation was elevated in obese-IGT and obese-diabetic P. obesus and was 
positively correlated with body weight.  Several studies in humans have found 
increased fat oxidation in obese subjects (Felber et al., 1987; Niskanen et al., 
1997).  Glucose and protein oxidation rates are tightly regulated to maintain 
net glucose and protein balance respectively (Schutz et al., 1989; Jebb et al., 
1996).  In contrast fat oxidation is largely independent of fat intake and is 
quantitatively dependent on the difference between total energy requirements 
and energy derived from glucose and protein oxidation (Schutz et al., 1989).  
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The development of obesity, and the accompanying elevation in fat oxidation, 
may be sufficient to attain fat balance as body weight stabilises (Schutz et al., 
1989; Flatt, 1993). 
 
Short term fasting dramatically altered whole body energy metabolism in P. 
obesus.  Carbohydrate oxidation was substantially reduced and fat oxidation 
was increased in all animals.  The net result was a reduction in energy 
expenditure, independent of body weight.  Blood glucose levels and whole 
body glucose oxidation rates were not different between diabetic and 
nondiabetic animals, suggesting 24 hours of fasting is sufficient to match EGP 
to whole body glucose disposal in diabetic animals.   
 
Dietary energy restriction reduced body weight and normalised blood glucose 
and insulin levels in P. obesus.  Whole body glucose oxidation was reduced 
and fat oxidation was increased.  Glucose and fat oxidation rate were not 
different between groups.  Fat oxidation rates were not significantly increased 
in obese-diabetic animals.   This is most likely due to already elevated baseline 
fat oxidation rates in these animals.  Several studies in humans have 
demonstrated fat oxidation rates in post obese subjects are lower than in never 
obese controls (Astrup et al., 1994; Larson et al., 1995; Wyatt et al., 1999; 
Filozof et al., 2000; Weyer et al., 2000a).  However, several studies with mice 
or rats have found fat oxidation was increased (Boschmann et al., 1994) or 
unchanged (Chen and Heiman, 2000; Rohner-Jeanrenaud et al., 2002) with 
weight loss following dietary energy restriction.  The discrepancy between 
human subjects and either rodents or gerbils may represent different 
physiological responses to weight loss between species.  Alternatively 
different experimental design with respect to magnitude and rate of weight 
loss may also contribute to variability between studies, especially if some 
subjects remain in negative enrgy balance while others have maintained a 
stable body weight.  
 
Dietary energy restriction and fasting initially reduces blood glucose levels 
prior to the reduction in body weight, due to the reduction in glucose intake 
and decreased EGP (Christiansen et al., 2000).  Subsequent improvements in 
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the blood glucose and lipid profiles are likely to be mediated through reduced 
EGP, although peripheral insulin sensitivity and glucose effectiveness are also 
improved (Christiansen et al., 2000). 
 
Insulin resistance increases with weight gain and decreases with weight loss 
(Ferrannini et al., 1991; Ferrannini et al., 1997).  Therefore, visceral adiposity, 
which drains directly to the liver via the portal vein may potentially mediate 
the relationship between insulin resistance and body weight, as the liver is 
exposed to an increased flux of FFA and precursors for glucose synthesis, 
promoting hepatic glucose production and very low density lipoprotein 
(VLDL) secretion, and contributing to hepatic insulin resistance (Kissebah and 
Krakower, 1994).  Surgical removal of visceral fat has been shown to increase 
hepatic insulin sensitivity in rats (Barzilai et al., 1999).  Abdominal fat content 
was independently associated with blood glucose and plasma insulin 
concentrations in a large cross sectional study of P. obesus (Walder et al., 
2000), suggesting visceral adiposity is an important determinant of glucose 
metabolism in these animals.   
  
3.5.3 Diurnal Substrate Utilisation in Psammomys obesus  
Unlike other animal models of obesity and diabetes, P. obesus do not display 
circadian variation in food intake or physical activity levels.  In contrast rats 
consume more food and are most active during the dark phase (Mistlberger et 
al., 1998).  Rats also display circadian variations in blood glucose 
concentrations, which are controlled by the suprachiasmatic nucleus (la Fleur 
et al., 2001).  P. obesus may be a better model to explore the circadian 
variations in glucose homeostasis without the confounding effects of activity 
and food intake. 
 
Obese-diabetic P. obesus exhibited elevated fat oxidation rates and plasma 
glucose levels during the dark phase.  Increased activity levels and plasma 
FFA concentration can each increase fat oxidation (Jequier, 1998), however 
neither of these factors were associated with the elevated fat oxidation in P. 
obesus.  Boden et al (1996a) found nocturnal insulin sensitivity decreased and 
EGP increased in type 2 diabetic subjects.  Fasting EGP is elevated in obese-
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diabetic P. obesus (Barnett et al., 1995), however it is unclear if increased 
EGP is responsible for the nocturnal elevation in blood glucose levels as EGP 
was not measured in the present study.  Plasma insulin and cortisol levels did 
not display any diurnal variations and are therefore unlikely to be responsible 
for the nocturnal increase in plasma glucose and fat oxidation rates.  Further 
studies are necessary to determine the physiological significance of these 
metabolic disturbances. 
 
Lean-NGT P. obesus display a nocturnal elevation in plasma leptin 
concentration.  Similarly, studies in lean human subjects have found nocturnal 
increases (Sinha et al., 1996).  Basal plasma leptin concentrations in obese-
IGT and obese-diabetic P. obesus are elevated and these animals are extremely 
resistant to leptin administration, relative to lean-NGT animals (Walder et al., 
1997).  The absence of diurnal variations in obese-IGT and obese-diabetic P. 
obesus further supports the possibility of dysregulated leptin signalling in 
these animals. 
 
3.5.4 Summary 
Whole body energy expenditure and substrate utilisation in P. obesus were 
similar to that seen in humans, providing further validation of P. obesus as an 
ideal animal model of obesity and type 2 diabetes.  Energy expenditure and fat 
oxidation were elevated in obese-IGT and obese-diabetic animals.  After 
adjusting for body weight, neither energy expenditure nor fat oxidation were 
different between groups.  Short term fasting and dietary energy restriction 
normalised blood glucose and plasma insulin levels in obese-IGT and obese-
diabetic animals.  Dietary energy restriction also reduced body weight in all 
animals.  Energy expenditure, glucose oxidation and fat oxidation were not 
different between lean-NGT, obese-IGT and obese-diabetic animals after 
normalising blood glucose and plasma insulin concentrations. 
 
Obese-diabetic P. obesus exhibited elevated nocturnal fat oxidation rates and 
plasma glucose levels, independent of plasma insulin and cortisol levels.  
Further studies are necessary to elucidate the importance of these nocturnal 
fluctuations in glucose and fat metabolism in the pathogenesis of obesity and 
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diabetes in these animals.  Lean-NGT P. obesus display a nocturnal elevation 
in plasma leptin concentration, which is absent in obese-IGT and obese-
diabetic animals, supporting the dysregulation of leptin signalling in obese P. 
obesus. 
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Gene Discovery with SSH and cDNA Dot Blots 
 
4.1 ABSTRACT 
This study aimed to identify novel genes differentially expressed in the liver of 
lean-NGT and obese-diabetic Psammomys obesus.  Suppression subtractive 
hybridisation (SSH) was used to enrich cDNA library for differentially 
expressed genes.  cDNA dot blots were used to screen 576 clones with cDNA 
derived from lean-NGT and obese-diabetic animals.  6 clones were identified 
as overexpressed in lean-NGT animals and 6 were overexpressed in obese-
diabetic animals.  These 12 clones were sequenced and SYBR-Green PCR was 
used to confirm differential gene expression.  4 genes were overexpressed 
(>1.5 fold) in lean-NGT animals and 4 genes were overexpressed (>1.5 fold) 
in obese-diabetic animals.   
 
To explore the physiological role of these genes, hepatic gene expression was 
examined in several physiological conditions.  Another, larger cohort of P. 
obesus with ad libitum access to food was used.  In addition, a cohort of P. 
obesus were fasted for 24 hours and another cohort were restricted to 67% of 
their usual food intake for 14 days, prior to being sacrificed.   
 
One gene, encoding thyroxine binding globulin (TBG), was confirmed as 
overexpressed in lean-NGT P. obesus with ad libitum access to food, relative 
to both obese-IGT and obese-diabetic animals.  TBG expression decreased 
with fasting in all animals.  Fasting TBG expression remained greater in lean-
NGT animals than obese-IGT and obese-diabetic animals.  TBG expression 
was not significantly affected by dietary energy restriction.  TBG is involved 
in thyroid metabolism and is potentially involved in the regulation of energy 
expenditure.   
 
Fasting increased hepatic site 1 protease (S1P) expression in lean-NGT 
animals but was not significantly affected in obese-IGT and obese-diabetic 
animals.  S1P expression was not significantly affected by dietary energy 
 86
GENE DICOVERY WITH SSH AND cDNA DOT BLOTS 
restriction.  S1P is involved in the proteolytic processing of steroid response 
element binding proteins (SREBP).  SREBPs are insulin responsive and are 
known to be involved in lipid metabolism.                                            
 
Gene expression studies found TBG and S1P were associated with obesity and 
diabetes.  Future research will determine whether TBG and S1P are important 
in the pathogenesis of these diseases. 
 
4.2  INTRODUCTION 
Type 2 diabetes mellitus is a polygenic disease characterised by defects in 
insulin secretion and insulin action, and disturbances in carbohydrate, fat and 
protein metabolism which are at least partly due to hepatic defects (ADA, 
2000; Gerich, 1991; Perriello et al., 1997).  P. obesus is a unique animal 
model of obesity and type 2 diabetes, ideally suited for studies aiming to 
identify novel genes involved in the pathophysiology of type 2 diabetes and 
obesity.  
 
Novel genes associated with diabetes can be identified using gene expression 
based approaches without prior knowledge of the disease process.  The 
primary limitation of this strategy is the large number of genes that are 
expressed within a tissue of interest at any given time (Bonaldo et al., 1996).  
Subtractive hybridisation based techniques can be used to screen this large 
number of genes to identify those of interest based on different levels of 
expression in diseased and control samples (Lisitsyn and Wigler, 1993).   
 
Suppression subtractive hybridisation (SSH) is novel a polymerase chain 
reaction (PCR) based subtractive hybridisation technique (Diatchenko et al., 
1996).  Target cDNA fragments are enriched by favourable hybridisation 
kinetics and PCR amplification (Hubank and Schatz, 1999).  The enriched 
cDNA library can be cloned and putatively differentially expressed genes can 
be screened with cDNA dot blots.   
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The current study was undertaken to identify genes differentially expressed in 
the liver of lean-NGT and obese-diabetic Psammomys obesus, utilising SSH 
and cDNA dot blots.  It was hypothesised that these genes could represent 
significant factors in the pathophysiology of type 2 diabetes.   
 
4.3 RESEARCH DESIGN AND METHODS 
Research design and methods are discussed in detail in Chapter 2 and 
described briefly below.   
 
4.3.1 Suppression Subtractive Hybridisation 
SSH studies used 18-week old lean-NGT (n=3) and obese-diabetic (n=3) 
Psammomys obesus.  These were designated as SSH animals and had ad 
libitum access to food.  Body weight, blood glucose (Yellow Springs 
Instruments, Yellow Springs, USA) and plasma insulin were measured 
(Insulin RIA, Phadeseph, Uppsala, Sweden).  Two SSH experiments were 
conducted using the PCR-Select cDNA subtraction kit (Clontech, Palo Alto, 
U.S.A.).  Experiment 1 was designed to enrich a cDNA pool for genes 
overexpressed in the liver of lean-NGT Psammomys obesus.  Conversely, 
experiment 2 was designed to enrich cDNA for genes overexpressed in obese-
diabetic Psammomys obesus.   
 
4.3.2 Cloning and cDNA Reamplification 
The enriched cDNA from the SSH experiments 1 and 2 were cloned using the 
T/A Cloning Kit Invitrogen, Carlsbad, USA).  The PCR products were ligated 
into a pCR2.1 plasmid vector and chemically transformed into TOP10 E. coli 
cells.  White colonies, representing successfully transfected clones, were 
selected and grown overnight.  These clones were amplified by PCR and used 
to prepare cDNA dot blots. 
 
4.3.3 cDNA Dot Blots Screening 
Two identical nylon membranes (Bright-Star Plus, Ambion, Austin, USA) 
were prepared for cDNA dot blots, using The PCR Select Differential 
Screening Kit (Clontech, 1999).  The PCR products representing the positive 
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clones were transferred onto nylon membranes using a dot blot apparatus 
(Biorad, Anaheim, USA) and cross-linked using a UV Stratalinker at 120mJ 
(Stratagene, Austin, USA).   
 
The enriched cDNA from experiment 1 and 2 were used to prepare tester and 
driver probes respectively.  Probes were each allowed to hybridise to the nylon 
membrane.  Membranes were exposed to a phosphorous plate and examined 
with a phosphorimager (Molecular Dynamics, Sunnyvale, USA).  A clone was 
identified as overexpressed in lean-NGT P. obesus when a stronger signal was 
detected from the tester probe than the driver probe.   
 
4.3.4 Sequencing and Bioinformatics 
Putatively overexpressed clones were reamplified from bacteria with PCR, 
visualised on an agarose gel with electrophoresis and excised.  cDNA was 
purified using the UltraClaean GelSpin DNA Purification Kit (Mo Bio 
Laboratories, Solana Beach, USA).  cDNA was sequenced by DyeDeoxy 
Terminator (Applied Biosystems, Foster City, USA) using an automated DNA 
sequencer (Applied Biosystems, Foster City, USA).  
 
Sequences were examined for homology with known genes or expressed 
sequence tags (ESTs), using blast searches of databases at the National Center 
for Biotechnology Information (http://www.ncbi.nlm.nih.gov).   
 
4.3.5 Gene Expression Studies 
To validate the differential expression identified with cDNA dot blot screening 
and to explore the physiological role of the genes identified, three sets of gene 
expression studies were conducted.  Firstly, to confirm the cDNA dot blot 
results, gene expression was examined in the lean-NGT and obese-diabetic 
SSH animals.  Secondly, to explore any potential role in energy metabolism, 
gene expression was examined in fed and fasted P. obesus.  Lean-NGT, obese-
IGT and obese-diabetic animals were included.  Thirdly, to further explore any 
metabolic role, gene expression was examined in fed and dietary energy 
restricted P. obesus.  Lean-NGT, obese-IGT and obese-diabetic animals were 
included.   
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Gene expression studies utilised SYBR Green PCR used the ABI Prism 7700 
Sequence Detection System (Applied Biosystems, Foster City, USA).  Primer 
were designed with Primer Express software (Version 1.5, Applied 
Biosystems, Foster City, USA).  Gene expression was normalised to 
cyclophillin, an enogenous control.  Dissociation curve analysis (Applied 
Biosystems, Foster City, USA) was used with the ABI Prism 7700 Sequence 
Detection System (Applied Biosystems, Foster City, USA) to determine if a 
single PCR product was generated with the SYBR Green PCR.   
 
4.3.5.1 Fasting 
18-week old lean-NGT (n=15), obese-IGT (n=16) and obese-diabetic (n=13) 
P. obesus were separated into fed and fasted groups.  Groups were matched 
for sex and body weight.  Fed animals had ad libitum access to food, whereas 
food was withdrawn from the fasted animals for 24 hours.  Body weight, 
blood glucose and plasma insulin were measured at the beginning and end of 
the fasting period.   
 
4.3.5.2 Dietary Energy Restriction 
At 18 weeks of age lean-NGT (n=13), obese-IGT (n=15) and obese-diabetic 
(n=12) P. obesus underwent 24 hours of indirect calorimetry with an Oxymax 
Equal Flow Indirect Calorimeter (Columbus Instrument, Ohio, USA) to 
measure fat oxidation, carbohydrate oxidation, respiratory quotient (RQ) and 
total energy expenditure (TEE).  Physical activity was measured while animals 
were in the calorimeter using the Opto-Varimax Mini-Infrared Animal 
Activity Monitoring System (Columbus Instruments, Ohio, USA).   
 
Animals had ad libitum access to food and water.  Animals were separated 
into fed and restricted groups for a 14 day experimental period.  Groups were 
matched for sex and body weight.  Fed animals had ad libitum access to food, 
whereas restricted animals were given 66 percent of the average food intake of 
their respective group during the baseline period.  Body weight and food 
disappearance were measured daily.  At the completion of the restriction 
period blood samples were taken and animals were placed in the indirect 
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calorimeter for another 24 hours.  Blood glucose and plasma insulin were 
measured.   
 
4.3.6 Statistical Analysis 
Statistical analysis was conducted using SPSS (Version 10, SPSS inc, 
Chicago, USA).  A Kolmogorov-Smirnov test was used to examine the 
distribution of data.  Normally distributed data in two groups was assessed 
using an independent samples T-test.  Data in three or more groups was 
assessed using one way ANOVA, with the LSD post hoc test when variance 
between groups was homogeneous, and with the Games-Howell post hoc test 
when variances were not homogenous.  Non-normally distributed data was 
analysed using a Mann-Whitney test.  The relationship between linear 
variables was assessed using Pearson and Spearman correlations for normally 
and non-normally distributed data respectively.  Statistical significance was set 
at p<0.05.   
 
4.4 RESULTS 
4.4.1 Suppression Subtractive Hybridisation 
Lean-NGT and obese-diabetic P. obesus were selected for gene discovery 
studies, allowing for the identification of genes differentially expressed with 
diabetes as well as obesity.  P. obesus were male and 18 weeks of age.  
Phenotypic data is shown in Table 4.1.    
 
Experiment 1 enriched a cDNA pool for genes overexpressed in lean-NGT P. 
obesus.  β actin was visible on an agarose gel after 15 cycles of PCR with non 
enriched cDNA (Figure 4.1a).  In contrast, β actin was visible after 25 cycles 
with enriched cDNA.  This 10 cycle difference corresponds to an approximate 
1000 fold enrichment of overexpressd genes.  Experiment 2 enriched cDNA 
for genes overexpressed in obese-diabetic P. obesus.  β actin was visible 10 
cycles later in enriched cDNA than non enriched, corresponding to a 1000 fold 
enrichment (Figure 4.1b).  As further confirmation of enrichment, G3PDH 
expression in experiments 1 and 2 were reduced approximately 1000 fold 
(data not shown). 
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Table 4.1 Phenotypic data for the P. obesus used in SSH experiments.  Data 
expressed as mean + SEM.   
 
 
 
 Lean-NGT Obese-Diabetic 
n 3 3 
Body Weight 
(g) 
210.7 + 7.8 245.3 + 2.9 
 
 Blood Glucose 
(mmol/l) 
3.9 + 0.4 9.7 + 0.3 
 
 
Plasma Insulin 
(µU/ml) 
64 + 17 481 + 200 
 
 
 
 
1a 1b 
15  20  25   30   35 15  20  25   30   35 
Non-enriched Non-enriched
Enriched Enriched 
 
 
 
 
 
 
 
Figure 4.1.  β actin PCR products from SSH experiments 1 (4.1a) and 2 (4.1b) 
visualised on a 1% agarose gel.  PCR products from enriched and non-
enriched cDNA were amplified for 15, 20, 25, 30 and 35 cycles. 
 
4.4.2 cDNA Dot Blots Screening  
Putatively overexpressed clones from lean-NGT (n=288) and obese-diabetic 
P. obesus (n=288) were screened with cDNA dot blots.  Blots were hybridised 
with cDNA from experiment 1 (lean-NGT enriched) and experiment 2 (obese-
diabetic enriched).  6 clones were identified as overexpressed in lean-NGT P. 
obesus and 6 clones overexpressed in obese-diabetic P. obesus.  A 
representative pair of cDNA dot blots are shown in Figure 4.2.  These 12 
differentially expressed genes were sequenced.  Blast searches of the NCBI 
databases (http://www.ncbi.nlm.nih.gov), 9 clones showed homology with 
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known genes (Table 4.2).  The remaining 3 clones did not show significant 
homology with known genes or (EST’s) on NCBI databases.   
 
  1  2  3  4   5  6   7  8   9  10 11 12
 A
 B
 
 
 
 
 
C
E
F
 
A
B
C 
DD
4.4.3 Gene Expression Studies  
4.4.3.1 SSH Animals 
First stage confirmation of these putatively differentially expressed genes 
involved measuring gene expression in the liver of the animals used to 
generate the enriched cDNA (Table 4.1).  4 genes showed 1.5 fold or more 
overexpression in lean-NGT animals (Table 4.2) and 4 genes showed 1.5 fold 
or more overexpression in obese-diabetic animals (Table 4.3).   
 
Table 4.2.  Clones overexpressed in lean-NGT P. obesus.   Homologies with 
known genes and ESTs on NCBI databases.  Overexpression presented as the 
ratio of expression of lean-NGT to obese-diabetic animals.   
 
Clone Gene Homology Genebank 
Accession no. 
Overexpression
AGT 12 Cytochrome P450,  
Subunit IIa 
NM000766 5.1 
AGT 16 Novel N/A 1.2 
AGT 18 Zinc Finger Protein 274 BC009763 0.7 
AGT 24 C Reactive Protein X17496 4.5 
AGT 32 Thyroxine Binding 
Globulin 
M63991 7.7 
AGT 33 Cytochrome P450, 
Subunit IIIa 
AB039380 7.0 
 
 
 
 
 
 
G
H
Figure 4.2.  cDNA dot blots probed with α32P labelled tester (4.2a) and 
driver (4.2b) enriched cDNA.  Open squares indicate clones displaying 
evidence of overexpression. 
 1  2  3  4   5  6   7  8   9  10 11 12
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Table 4.3.  Clones overexpressed in obese-diabetic P. obesus.   Homologies 
with known genes and ESTs on NCBI databases.  Overexpression of obese-
diabetic genes is presented as the ratio of expression of obese-diabetic to lean-
NGT animals. 
 
Clone Gene Homology Genebank 
Accession no. 
Overexpression
AGT 7 Site 1 Protease NM053569 1.3 
AGT 8 Novel N/A 1.5 
AGT 22 Novel N/A 1.5 
AGT 27 MS4A4 AB013102 1.5 
AGT 30 HSPC055 AF161540 1.7 
AGT 31 Huntington-Interacting 
Protein 
AJ238403 1.5 
 
4.4.3.2 Fed and Fasted Animals 
Second stage confirmation involved determining gene expression in a different 
and larger subset of animals.   Lean-NGT obese-IGT and obese-diabetic P. 
obesus were used.  To further elucidate any potential role in energy 
metabolism another set of lean-NGT obese-IGT and obese-diabetic P. obesus 
sacrificed after 24 hours of fasting were also included.  Phenotypic data for 
these animals is shown in Table 4.4.  Previous studies with P. obesus have 
shown 24 hour fasting is associated with reduced total energy expenditure and 
carbohydrate oxidation, and increased fat oxidation (Chapter 3.4).  Fasting 
also normalises blood glucose and plasma insulin levels in obese-IGT and 
obese-diabetic groups (Chapter 3.4). 
 
Table 4.4.  Phenotypic data for fed and fasted P. obesus.  Data expressed as 
mean + SEM.  * Indicates a significant difference compared to lean-NGT 
animals (p<0.05).  # Indicates a significant difference compared to fed animals 
(p<0.05). 
Lean-NGT Obese-IGT Obese-Diabetic  
Fed Fasted Fed Fasted Fed Fasted 
n 8 7 8 8 7 6 
Body Weight 
(g) 
179.9 
+ 3.2 
190.6 + 
7.7 
232.9 
+ 6.1* 
229.3 
+ 7.5* 
244.8 
+ 5.2* 
249.8 
+ 14.1*
Blood Glucose 
(mmol/l) 
4.3 
+ 0.2 
3.7 
+ 0.3 
4.8 
+ 0.3 
3.8 
+ 0.3# 
14.2 
+ 1.2* 
9.5 
+ 1.8*#
Plasma Insulin 
 
(µU/ml) 
52 
+ 6 
28 
+ 4# 
373 
+ 66* 
89 
+ 19*# 
727 
+ 1.2* 
119 
+ 23*# 
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Using SYBR Green PCR in the larger group of animals, only AGT 32 
displayed significantly greater gene expression in lean-NGT P. obesus relative 
to obese-diabetic P. obesus.  This gene encoded Thyroxine Binding Globulin 
(TBG) (Figure 4.3).  The 350 nucleotides of P. obesus TBG is 91 percent 
homologous to rat TBG (Genebank accession no. M63991) and 78 percent 
homologous to human TBG (Genebank accession no. M14019).   
 
Hepatic TBG gene expression in P. obesus is shown in Figure 4.4.  Expression 
was significantly greater in lean-NGT animals than obese-IGT (p=0.001) and 
obese-diabetic animals (p=0.003).  TBG expression was reduced with fasting 
in all groups (p=0.039).  Furthermore, amongst fasted P. obesus TBG 
expression was greater in lean animals than obese-IGT (p=0.014) and obese-
diabetic (p=0.018) groups.  TBG expression was negatively correlated with 
body weight (r=0.40, p=0.007, Figure 4.5a) and plasma insulin concentration 
in these animals (r=0.30, p=0.049, Figure 4.5b).  SYBR Green PCR in the 
larger group of animals did not confirm any of the genes identified as 
overexpressed in obese-diabetic P. obesus.   
 
CTACTTTTTCAATTACTCTTTTATTGGATTAACAACTTTCCCTAAAAAGAGA
ATGCTTTTGGTTCTTTTCTCCAAAATCATCAGTAAGAATGTTCTATCAAATC
TAATAACAGGGTGAAGAGAAGCTACTTCTGCCTGATCCAGAGAGCCAGCTTC
AGGAGTAGCTTCTTCTTTGGTTCCTTCTTCTCCAATGTGCAGCACAGCCTTG
TGAAAAGCATAGGAAAGTTTTAAACCATTGTCTTCTGTGATTCTAGAAAAGT
CAGCACTTTCAGCAAAGGCATCCCTCATGCCCATCTTCTGAAGTGTGCTTCC
AAGGTCATATGTGGCAGAAATGGAAAACTTTGGAACAA 
Figure 4.3.  TBG nucleotide sequence in P. obesus. 
 
AGT 7 gene expression was less than 1.5 fold different between lean-NGT 
and obese-diabetic P. obesus and was therefore not confirmed during the first 
stage of confirmation.  However, the Blast search of the NCBI database found 
AGT 7 encoded site 1 protease (S1P) (Figure 4.6).  The 480 nucleotides of P. 
obesus is 93 percent homologous to rat S1P (Genebank accession no. 
NM053569) and 91 percent homologous to human S1P (Genebank accession 
no. NM003791).  S1P is a substilisin-related protease that cleaves sterol 
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regulatory element-binding proteins (SREBPs).  SREBPs are transcription-
regulating proteins, involved in feedback systems that regulate multiple 
enzymes in the cholesterol and fatty acid biosynthesis pathways (Brown and 
Goldstein, 1999; Osborne, 2000).  Given the known role of S1P in 
metabolism, S1P gene expression was examined for further association with 
diabetes or obesity in fed and fasted P. obesus.   
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Figure 4.4.  TBG gene expression in fed and fasted P. obesus.  Data expressed 
as mean + SEM.  * Indicates a significant difference compared to lean-NGT 
animals (p<0.05).  # Indicates a significant difference compared to fed animals 
(p<0.05). 
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Figure 4.5.  Linear correlation between TBG gene expression and body 
weight (4.5a) and plasma insulin (4.5b) in P. obesus. 
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Hepatic S1P gene expression is fed and fasted P. obesus is shown in Figure 
4.7.  S1P expression was not different between lean-NGT, obese-IGT and 
obese-diabetic P. obesus in the fed state.  Gene expression was elevated in 
fasted compared to fed P. obesus when groups were combined (p=0.003).   
 
GAGGGATGNGGACAATGGCCTTTCCTTGTCATCTTTAAGTGACTGGTACAAC
ACTTCTGTTATGAGAAAAGTGAAATTTTATGATGAAAACACAAGGCAGTGGT
GGATGCCAGATACTGGAGGAGCCAACATCCCAGCTCTGAATGAGCTGCTGTC
TGTATGGAACATGGGGTTCAGTGACGGCCTGTATGAAGGGGAATTTGTCCTG
GCAAACCATGACATGTATTATGCGTCGGGGTGCAGCATCGCCAGGTTTCCAG
AAGATGGTGTTGTGATCACACAGACTTTCAAGGATCAAGGATTGGAGGTCTT
AAAACAAGAGACAGCAGTTGTTGAAAATGTTCCCATTTTGGGGCTTTATCAG
ATTCCAGCTGAAGGTGGAGGTCGTATTGTGCTGTATGGAGACTTCAACTGCT
TGGATGACAGTCACAGACAGAAGGACTGNTTTTGGCTTCTGGATGCGCTCCT
TNAGTACCTCGG 
Figure 4.6.  S1P nucleotide sequence in P. obesus.   
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Figure 4.7.  S1P gene expression in fed and fasted P. obesus.  Data expressed 
as mean + SEM.  * Indicates a significant difference compared to lean-NGT 
fasted animals (p<0.05).  # Indicates a significant difference compared to fed 
animals (p<0.05). 
#
#
* *
4.4.3.3 Fed and Dietary Energy Restricted Animals 
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To further elucidate the potential role of TBG in metabolism, gene expression was 
examined in dietary energy restricted P. obesus.  Phenotypic data for fed and 
energy restricted and control animals are shown in Table 4.5.  Previous studies 
have shown 14 days of dietary energy restriction reduced body weight in all 
groups and normalised blood glucose and insulin levels in obese-IGT and obese-
diabetic groups (Chapter 3.4).  Total energy expenditure decreased in proportion 
to body weight, glucose oxidation was decreased and fat oxidation increased 
(Chapter 3.4). 
 
Table 4.5.  Phenotypic and metabolic data for fed and energy restricted P. 
obesus.  Data expressed as mean + SEM.  * Indicates a significant difference 
compared to lean-NGT animals (p<0.05).  # Indicates a significant difference 
compared to fed animals (p<0.05). 
Lean-NGT Obese-IGT Obese-Diabetic  
Fed Rest Fed Rest Fed Rest 
n 8 8 8 8 8 8 
Body Weight 
(g) 
231.7 
+ 9.4 
215.0 
+ 7.5 
242.0 
+ 5.6 
223.8 
+ 8.7 
251.8 
+ 8.8 
236.7 
+ 4.6* 
Body Fat 
(%) 
3.3 
+ 0.3 
2.1 
+ 0.4# 
3.7 
+ 0.3 
2.5 
+ 0.3# 
4.5 
+ 0.2* 
3.7 
+ 0.3* 
Blood Glucose 
(mmol/l) 
4.0 
+ 0.2 
4.3 
+ 0.4 
4.4 
+ 0.5 
3.6 
+ 0.4 
12.4 
+ 2.7* 
4.6 
+ 0.5# 
Plasma Insulin 
(µU/ml) 
91 
+ 18 
72 
+ 17 
303 
+ 67 
37 
+ 12# 
275 
+ 60 
58 
+ 20 
TEE 
(kJ/day) 
109 
+ 9 
115 
+ 7 
1.21 
+ 7 
115 
+ 5 
136 
+ 7* 
127 
+ 7 
Fat Oxidation 
(mg/min) 
0.54 
+ 0.01 
0.86 
+ 0.08 
0.57 
+ 0.01 
0.86 
+ 0.06#
0.90 
+ 0.10 
1.0 
+ 0.1 
CHO Oxidation 
 
(mg/min) 
1.9 
+ 0.2 
1.6 
+ 0.2 
1.9 
+ 0.2 
1.7 
+ 0.2 
1.9 
+ 0.2 
1.6 
+ 0.1 
Gene expression studies in these animals was not normalised to a housekeeping 
gene, as cyclophilin expression in lean-NGT animals was different between fed 
and dietary energy restricted groups (p<0.05).  Gene expression data was 
therefore normalised to an arbitrary value.  The TBG expression profile 
previously seen in fed; lean-NGT, obese-IGT and obese-diabetic animals was 
reproduced in these fed animals (Figure 4.8).  TBG expression was in lean-NGT 
animals was significantly greater than obese-diabetic animals (p=0.004) and 
tended to be greater than obese-IGT animals  
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(p=0.066).  TBG expression was not significantly affected by dietary energy 
restriction in P. obesus.  Furthermore, TBG expression was not correlated with 
adiposity, blood glucose or insulin levels, energy expenditure, or fat and 
glucose oxidation rates. 
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Figure 4.8.  TBG gene expression in fed and dietary energy restricted P. 
obesus. Data expressed as mean + SEM. 
 
To further elucidate the potential role of S1P in metabolism, gene expression 
was examined in fed and dietary energy restricted P. obesus.  S1P gene 
expression is shown in Figure 4.9.  S1P expression was not significantly 
different between lean-NGT, obese-IGT and obese-diabetic P. obesus, and did 
not change with dietary energy restriction.  S1P expression did not correlate 
with adiposity, blood glucose or insulin levels, energy expenditure, or fat and 
glucose oxidation rates. 
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Figure 4.9.  S1P gene expression in fed and dietary energy restricted P. 
obesus. Data expressed as mean + SEM. 
 
4.5 DISCUSSION 
SSH and cDNA dot blot screening identified 12 genes potentially 
differentially expressed in lean-NGT and obese-diabetic P. obesus.  SYBR 
Green PCR confirmed 8 genes were at least 1.5 fold differentially expressed.  
The inability to confirm all but one of the 8 genes in a different subset of 
animals does not indicate a failure of either the SSH or cDNA dot blot 
techniques, as a 1000 fold enrichment of overexpressed genes was achieved.  
Furthermore, 67% of the genes identified exceeded the 1.5 fold overexpression 
reported to be the sensitivity level of the SSH technique (Clontech, 2000).  
Each of these genes may potentially contribute to the diabetes phenotype of 
these animals, however they are unlikely to be common causes in P. obesus 
given they were only differentially expressed in a small subset of animals.   
 
Experimental groups were sex and age matched, and there was no indication 
that the animals selected were not representative of the lean-NGT obese-IGT 
and obese-diabetic groups they were classified into.  However, P. obesus do 
not fall into discrete categories of diabetic and non-diabetic.  Blood glucose 
and insulin levels are continuous variables, and the relationship between them 
resembles an inverted U shape (Barnett et al., 1994a), similar to that seen in 
humans (DeFronzo, 1988).  The polygenic and heterogenous nature of type 2 
diabetes in these animals makes it unlikely that two samples of diabetic 
animals will exhibit identical genotypes.  Increasing the sample size in future 
SSH studies will increase the likelihood of reproducing results in different 
samples of animals.  Genes that are differentially expressed in the majority of 
lean-NGT and obese-diabetic P. obesus are more likely to represent significant 
factors in the pathophysiology of type 2 diabetes.   
 
The magnitude of differential expression of many metabolic genes may be less 
than 1.5 fold and therefore fall below the sensitivity level of the SSH 
technique (Clontech, 2000).  The magnitude of differential expression between 
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groups does not necessarily relate to the magnitude of the physiological effect.  
For some tightly controlled metabolic genes a difference in gene expression of 
less than 1.5 fold may result in a significant physiological effect, whereas as a 
2-3 fold difference in other genes may be physiologically ineffectual 
(Strausberg and Riggins, 2001).  The SSH technique is a screening procedure 
designed to increase the likelihood of identifying genes differentially 
expressed more than 1.5 fold, the physiological effect of the differential gene 
expression does not influence the procedure. 
 
TBG was identified as differentially expressed between lean-NGT and obese-
diabetic P. obesus following the screening of 576 clones with cDNA dot blots.  
It is difficult to speculate on how many genes may be significantly 
differentially expressed between these two animal groups and how many 
genes need to be screened to identify them.  Furthermore, the unknown level 
of redundancy in the enriched library makes such estimations even more 
difficult. It is possible that identification of 10 or more differentially expressed 
genes may require screening 6000 or more clones.  Screening such a large 
number of clones with cDNA dot blots is impractical.  cDNA microarray 
technology is an alternative approach that allows up to 20,000 clones to be 
screened simultaneously (Wildsmith and Elcock, 2001).  Utilising SSH and 
cDNA microarray should facilitate the identification of many more 
differentially expressed genes. 
 
 
4.5.1 Thyroxine Binding Globulin 
Hepatic TBG expression was dramatically reduced in obese-diabetic P. obesus 
relative to lean-NGT P. obesus.  Furthermore, TBG expression decreased with 
fasting.  These results suggest TBG metabolism may be involved in energy 
metabolism.  TBG is a plasma protein that binds the thyroid hormones (TH) 
thyroxine (T4) and triiodothyronine (T3) (Bartalena and Robbins, 1992).  TH 
administration was one of the first pharmacological obesity treatments as 
administration of TH dramatically increases energy expenditure (Krotkiewski, 
2000). 
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TH influence many metabolic pathways, including carbohydrate, fat and 
protein metabolism.  TH increase endogenous glucose production, through 
increased gluconeogenesis, while also increasing glucose utilisation 
(Dimitriadis and Raptis, 2001).  TH also stimulates triglyceride release from 
adipose tissue, increasing plasma free fatty acid concentrations as well as 
increasing lipid utilisation (Dimitriadis and Raptis, 2001).  The paradoxical 
increase in glucose and fat production and utilisation may represent futile 
substrate cycling, increasing energy expenditure.   
 
The calorigenic action of TH is divided into short term effects, lasting from 6 
to 48 hours, and long term effects, lasting from 30 hours up to 60 days 
(Krotkiewski, 2000).  Short term effects involve diiodothyronine (T2), an 
active metabolite of T3, directly interacting with mitochondrion enzymes 
including subunit Va of cytochrome c oxidase, resulting in enhanced 
respiration and heat dissipation (Krotkiewski, 2000).  Long term effects 
involve interaction between T3 and the nuclear TH receptors (TRs). TRs bind 
to regulatory regions of genes containing thyroid response elements.  Many 
genes are activated including fatty acid synthase, hepatic lipoprotein lipase, 
glucose 6 pyruvate dehydogenase, malate dehydrogenase, Ca++ ATPase and 
Na+K+ ATPase and the uncoupling proteins (UCPs).  Activation of UCPs 
have been proposed as a primary mechanism of TH mediated elevation of 
energy expenditure (Krotkiewski, 2000). 
 
TBG is produced in the liver, and along with albumin and TBG-pre albumin 
binds plasma TH.  Approximately 70 percent of plasma T4 and T3 are bound 
to TBG, with less than 0.03 percent of T4 and 0.3 percent of T3 are free in the 
circulation and physiologically active (Bartalena and Robbins, 1992).  
Elevated TBG levels are associated with a reduction in free TH levels.  This 
situation is rapidly corrected with an increase in thyroid stimulating hormone 
(TSH) release and a subsequent stimulation of TH synthesis and release.  The 
net result is an increase in bound TH and normal levels of free TH (Bartalena 
and Robbins, 1992). 
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Genetic mutations in TBG can cause complete TBG deficiency, which is 
associated with very low total T4 and T3 levels and elevated plasma free T3 
and T4 concentrations (Mori et al., 1990; Li et al., 1991a; Yamamori et al., 
1991; Ueta et al., 1997; Carvalho et al., 1998a; Carvalho et al., 1998b).  
Mutations can also cause an excess of TBG, increasing total plasma TH levels 
(Griffiths et al., 1985; Mori et al., 1995).  It is unclear if TBG mutations 
influence body weight, energy expenditure or substrate utilisation.   
 
The current study found TBG expression decreased with fasting in P. obesus.  
Fasting has previously been associated with reduced levels of T3, TBG, 
blunted response to TSH and TRH and decreased tissue sensitivity to T3 
(Krotkiewski, 2000).  Down regulation of the thyroid system is consistent with 
the reduced energy expenditure accompanying fasting in P. obesus (Chapter 
3.4) which represents a compensatory mechanism to conserve energy. 
 
TBG expression was reduced in obese P. obesus, suggesting a reduction in 
TBG activity may contribute to the pathophysiology of obesity, potentially 
mediated by TH.  Although speculative, a potential reduction in energy 
expenditure may be small, or localised to a subset of tissues, and below the 
sensitivity level of the whole body indirect calorimetry system, as obese P. 
obesus do not manifest a gross defect in energy expenditure (Chapter 3.4).  
Disproportionately low energy expenditure, mediated by TBG, in pre-obese P. 
obesus could lead to obesity.  The compensatory increased energy expenditure 
associated with the increased body weight could be sufficient to overcome the 
low TH mediated energy expenditure.  Alternatively, TBG may contribute to 
the development of obesity independently of its role in binding plasma T4 and 
T3.  Further research is necessary to elucidate any potential role of TBG in 
metabolism. 
 
4.5.2 Site 1 Protease 
Hepatic S1P expression increased with fasting in lean-NGT, but not obese-
IGT and obese-diabetic P. obesus, suggesting that S1P may potentially be 
involved in energy metabolism.  S1P is a protease that cleaves sterol 
regulatory element-binding proteins (SREBPs).  SREBPs are transcription-
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regulating proteins, involved in feedback systems that regulate multiple 
enzymes in the fatty acid biosynthesis pathways including; acetyl CoA 
carboxylase, fatty acid synthase, steroyl, CoA desaturase-1 (Brown and 
Goldstein, 1999; Osborne, 2000).  SREBPs also activate transcription of genes 
involved in cholesterol biosynthesis including: HMG CoA synthase, HMG 
CoA reductase, farnesyl diphosphate synthase, squalene synthase, and genes 
for the low density lipoprotein receptor (Brown and Goldstein, 1999; Osborne, 
2000). 
 
The SREBP isoforms 1a and 1c are produced from a single gene, with isoform 
2 produced from a different gene (Hua et al., 1995; Shimano et al., 1997a; 
Shimomura et al., 1999).  SREBPs are embedded in the endoplasmic 
recticulum.  Activation of SREBPs is initiated by SREBP cleavage activating 
protein (SCAP), which transports the SREBPs to the golgi, where they 
undergo proteolytic cleavage.  Cleavage occurs initially with S1P, and then 
with site 2 protease (S2P), releasing the transcriptionally active NH(2)-
terminal fragments which translocate to the nucleus (Brown and Goldstein, 
1999).   
 
The physiological role of the SREBP system has been studied extensively with 
gene knockout and transgenic overexpression studies in mice.  Hepatic TG and 
cholesterol synthesis and content are increased when the hepatic expression of 
SREBP isoforms 1a (Shimano et al., 1997a), 1c (Shimano et al., 1997a) or 2 
(Horton et al., 1998b) are increased and also when SCAP expression is 
increased (Korn et al., 1998).  Whole body knockout of SREBP 1a and 1c 
(Shimano et al., 1997b) and hepatic knockout of 1c (Liang et al., 2002) 
increased hepatic cholesterol synthesis and content, largely due to 
overexpression of SREBP 2, which is preferentially involved in cholesterol 
metabolism.  Hepatic knockout of SCAP (Matsuda et al., 2001) or S1P (Yang 
et al., 2001) decreases activity of all the SREBPs, decreasing hepatic synthesis 
and storage of TG and cholesterol.  Paradoxically plasma TG concentrations 
decrease with all the genetic manipulations described above.  Plasma 
cholesterol levels decrease in all studies with the exception of the transgenic 
overexpression of either SREBP 1c or 2, which have no effect.  Taken 
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together these studies suggest the most favourable lipid metabolism profile 
occurs when the activity of all SREBPs is decreased at the level of SCAP or 
S1P.   
 
24 hour fasting increases SREBP activity and hepatic TG and cholesterol 
synthesis (Horton et al., 1998a) and is accompanied by increased fat oxidation 
in P. obesus (Chapter 3.4).  The increased hepatic S1P expression with fasting 
in lean-NGT P. obesus is consistent with increased SREBP activity.  However, 
obese-IGT and obese-diabetic P. obesus do not significantly increase S1P 
expression, despite increased in fat oxidation.  Although speculative, a blunted 
SPEBP response to fasting may be a compensatory response to 
hypertriglyceridemia and hypercholesterolemia in these animals.  
 
Hepatic S1P expression was not different between lean-NGT, obese-IGT and 
obese-diabetic P. obesus, despite the presence of hyperinsulinemia, a strong 
stimulant of SREBP activity (Osborne, 2000).  Furthermore, hyperinsulinemic, 
P. obesus have hypertriglyceridemia and hypercholesterolemia, consistent 
with elevated SPEBP activity.  The role of S1P and SREBPs in lipid 
metabolism in P. obesus is uncertain and further studies are necessary to 
elucidate these roles. 
 
4.5.3 Summary 
SSH enriched a cDNA library 1000 fold for genes differentially expressed in 
the liver of lean-NGT and obese-diabetic P. obesus.  8 of the 12 genes 
identified form cDNA dot blots screening were differentially expressed by 1.5 
fold or more.  TBG was confirmed as differentially expressed in a different 
subset of P. obesus.  Identification of a larger number of genes differentially 
expressed genes will require the screening of several thousand clones.  Gene 
expression studies with SYBR Green PCR found TBG and S1P were 
associated with obesity and diabetes.  Future research will determine whether 
TBG and S1P are important in the pathogenesis of these diseases.
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Gene Discovery with SSH and cDNA Microarray 
 
5.1 ABSTRACT 
This study aimed to identify novel genes differentially expressed in the liver of 
lean-NGT and obese-diabetic Psammomys obesus.  Suppression subtractive 
hybridisation (SSH) was used to enrich a hepatic cDNA library for 
differentially expressed genes.  cDNA microarray was used to screen 8064 
clones with cDNA derived from lean-NGT and obese-diabetic animals.  223 
clones were identified as overexpressed in lean-NGT P. obesus and 274 clones 
were overexpressed in obese-diabetic P. obesus.   
 
The 9 most significantly differentially expressed clones identified from the 
microarray screen were sequenced.  7 novel genes were identified as well as; 
sulfotransferase related protein and albumin.  These 2 genes have not 
previously been associated with either type 2 diabetes or obesity.  It is unclear 
why hepatic expression of these genes may differ between lean-NGT and 
obese-diabetic groups of P. obesus.   
 
Future studies will utilise SYBR Green PCR to confirm differential expression 
of these genes, and measure hepatic expression levels in fed, fasted and dietary 
energy restricted P. obesus similar to experiments in Chapter 4.  Subsequent 
studies will explore the potential role of these novel and known genes in the 
pathophysiology of type 2 diabetes. 
 
5.2 INTRODUCTION 
The previous gene discovery experiment (Chapter 4) utilised suppression 
subtractive hybridisation (SSH) to enrich liver cDNA for genes differentially 
expressed between lean-NGT and obese-diabetic Psammomys obesus.  The 
enriched library was subsequently screened with cDNA dot blots.  Although 
this approach successfully screened several hundred genes, several thousand 
genes may need to be screened to identify important metabolic genes 
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associated with type 2 diabetes.  Such large scale screening requires a different 
approach.  
 
Microarray technology is advantageous compared to dot blots in several 
aspects.  Firstly, microscope slides can be exposed to two cDNA samples 
labelled with different fluorescent dyes simultaneously, allowing competitive 
hybridisations between the sample of interest and a control (Duggan et al., 
1999).  Secondly, microscope slides provide an impermeable surface, 
maximizing hybridisation rates and signal intensity (Southern et al., 1999).   
Thirdly, up to 20,000 clones can be screened simultaneously with cDNA 
microarray (Wildsmith and Elcock, 2001).   
 
The current study was undertaken to identify genes differentially expressed in 
the liver of lean-NGT and obese-diabetic Psammomys obesus, utilising SSH 
and cDNA microarray.   
 
5.3 RESEARCH DESIGN AND METHODS 
Research design and methods are discussed in detail in Chapter 2 and 
described briefly below.   
 
5.3.1 Suppression Subtractive Hybridisation 
SSH studies used 18-week old lean-NGT (n=4) and obese-diabetic (n=4) 
Psammomys obesus.  These were designated as SSH animals and had ad 
libitum access to food until they were killed.  Body weight, blood glucose 
(Yellow Springs Instruments, Yellow Springs, USA) and plasma insulin were 
measured (Insulin RIA, Phadeseph, Uppsala, Sweden).   
 
Two SSH experiments were conducted using the PCR-Select cDNA 
subtraction kit (Clontech, Palo Alto, U.S.A.).  Experiment 1 was designed to 
enrich a cDNA pool for genes overexpressed in the liver of lean-NGT 
Psammomys obesus.  Conversely, experiment 2 was designed to enrich cDNA 
for genes overexpressed in obese-diabetic Psammomys obesus.   
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5.3.2 Cloning 
The enriched cDNA from SSH experiments 1 and 2 were cloned using a T/A 
Cloning Kit (Invitrogen, Carlsbad, U.S.A.).  The PCR products were ligated 
into a pCR2.1 plasmid vector and chemically transformed into TOP10 E. coli 
cells (Invitrogen, Carlsbad, U.S.A.).  White colonies, representing successfully 
transfected clones, were selected and grown overnight.   
 
5.3.3 cDNA Microarray Screening 
5.3.3.1 PCR Amplification and Purification of Clones 
Clones from experiments 1 and 2 were PCR amplified in 384 well plates 
(Applied Biosystems, Foster City, USA) using 5’amino modified primers 
which were complementary to the bacterial vector pCR2.1 (Geneworks, 
Adelaide, Australia).  PCR products were purified using an ArrayIt, vacuum 
manifold system  (TeleChem International, Sunnyvale, USA).   
 
5.3.3.2 Printing Microarray Slides 
cDNA was resuspended in 20µl of ArrayIt spotting solution (TeleChem 
International, Sunnyvale, USA), and 5µl of resuspended cDNA was 
transferred to 384 well Uniplates (Whatman Inc, Clifton, USA).  cDNA was 
printed onto 40 microarray slides using an SDD C2 robotic arrayer 
(Engineering Services Inc, Toronto, Canada).   
 
5.3.3.3 Microarray Hybridisation Experiments 
Two groups of P. obesus were used for the microarray hybridisation 
experiments, including lean-NGT (n=10) and obese-diabetic (n=10).  The 
lean-NGT and obese-diabetic groups each included 4 SSH animals. 
 
Hybridisation experiments involved indirect labeling of target cDNA and 
reference cDNA with the fluorescent dyes Cy5 and Cy3 respectively 
(Amersham Pharmacia Biotech, Uppsala, Sweden).  The labeled cDNA was 
added to the microarray slides and a cover slip (Hybri-Slips, Sigma, St Louis, 
USA) was carefully placed on top.  The slides were placed in ArrayIt 
Hybridisation Cassettes (TeleChem, International Inc, Sunnyvale, USA).  
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Hybridisation chambers were incubated at 65°C for 20 hours.  Unincorporated 
cDNA was removed from the slides with a wash procedure.   
 
5.3.3.4 Microarray Data Analysis 
Microarray slides were scanned using a confocal microscope (ScanArray Lite, 
BioDiscovery Inc, Los Angeles, USA) with Gene Pix Pro software (Version 
3.0, Axon Instruments Inc, Union City, USA).  Median Cy5 and Cy3 signal 
intensities for each cDNA spot were imported from Gene Pix and data 
transformation was conducted using Genesight (Version 3, BioDiscovery Inc, 
Los Angeles, USA).  The ratio of Cy5 (sample cDNA) to Cy3 (reference 
cDNA) was calculated, providing a measure of the relative expression of each 
clone on the microarray slide in the cDNA sample hybridised to it.  This data 
was normally distributed, and gene expression analysis between two groups 
was assessed using an independent samples T test.   
 
5.3.4 Sequencing and Bioinformatics 
Putatively overexpressed clones were reamplified from bacteria with PCR, 
visualised on an agarose gel with electrophoresis and excised.  cDNA was 
purified using the UltraClaean GelSpin DNA Purification Kit (Mo Bio 
Laboratories, Solana Beach, USA).  cDNA was sequenced by DyeDeoxy 
Terminator (Applied Biosystems, Foster City, USA) using an automated DNA 
sequencer (Applied Biosystems, Foster City, USA).  
 
Sequences were examined for homology with known genes or expressed 
sequence tags (ESTs), using blast searches of databases at the National Center 
for Biotechnology Information (http://www.ncbi.nlm.nih.gov).   
 
5.3.5 Statistical Analysis 
Statistical analysis was conducted using SPSS (Version 10, SPSS inc, 
Chicago, USA).  A Kolmogorov-Smirnov test was used to examine the 
distribution of data.  Normally distributed data in two groups was assessed 
using an independent samples T-test.  Non-normally distributed data was 
analysed using a Mann-Whitney test.  Statistical significance was set at 
p<0.05.   
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5.4 RESULTS 
5.4.1 Suppression Subtractive Hybridisation 
Lean-NGT and obese-diabetic P. obesus were selected for gene discovery 
studies, allowing for the identification of genes differentially expressed with 
diabetes as well as with obesity.  All animals were male and 18 weeks of age 
(Table 5.1).  These animals were not used in any of the experiments in Chapter 
4. 
 
Experiment 1 enriched a cDNA pool for genes overexpressed in lean-NGT 
Psammomys obesus.  Figure 5.1a shows that β actin was visible on an agarose 
gel after 15 cycles in non-enriched cDNA and after 25 cycles in enriched 
cDNA.  Overexpressed genes were enriched over 1000 fold.  Experiment 2 
enriched cDNA over 1000 fold for genes overexpressed in obese-diabetic 
Psammomys obesus, as β actin was visible 10 cycles later in enriched cDNA 
(Figure 5.1b).  Expression of G3PDH in experiments 1 and 2 was also reduced 
by approximately 10 cycles (data not shown), confirming the 1000 fold 
enrichment of overexpressed genes in both SSH experiments.  
 
Table 5.1 Phenotypic data for the P. obesus used in SSH experiments.  Data 
expressed as mean + SEM.  * Indicates a significant difference compared  
to lean-NGT P. obesus (p<0.01). 
 
 
 Lean-NGT Obese-Diabetic 
n 10 10 
Body Weight 
(g) 
215 + 9.1 254 + 4.9*  
 Blood Glucose 
(mmol/l) 
4.0 + 0.2 13.4 + 1.4* 
 
Plasma Insulin  
 
(µU/ml) 
80 + 11 429 + 66* 
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Figure 5.1 β actin PCR products from SSH experiments 1 (5.1a) and 2 (5.1b) 
visualised on a 1% agarose gel.  PCR products from enriched and non-
enriched cDNA were amplified for 15, 20, 25, 30 and 35 cycles. 
 
5.4.2 cDNA Microarray Screening 
Putatively overexpressed clones from lean-NGT P. obesus (n=4224) and 
obese-diabetic P. obesus (n=3840) were screened with cDNA microarray.  
cDNA from lean-NGT and obese-diabetic animals were used for microarray 
experiments.  Phenotypic data for these animals are shown in Table 5.2.  The 
lean-NGT and obese-diabetic groups each included four animals from Table 
5.1 and six other animals.  These combinations were used to avoid selecting 
genes differentially overexpressed in animals used in the SSH experiment 
only, as occurred with the study in Chapter 4.   
 
Table 5.2 Phenotypic data for the P. obesus used in microarray screening.  
Data expressed as mean + SEM. * Indicates a significant difference compared 
to lean-NGT P. obesus (p<0.05). 
Lean-NGT Obese-Diabetic  
Fed Restricted Fed Restricted 
n 10 7 10 7 
Body Weight 
(g) 
215 + 9.1 215.0 + 7.5 254 + 4.9* 236.7 + 4.6 
Blood Glucose 
(mmol/l) 
4.0 + 0.2 4.3 + 0.4 13.4 + 1.4* 4.6 + 0.5# 
Plasma Insulin 
(µU/ml) 
80 + 11 72 + 17 429 + 66* 58 + 20# 
 
The expression of each clone on the microarray slide was measured in the 
cDNA of interest (labelled with Cy5) and in reference cDNA (labelled with 
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Cy3).  A strong linear relationship was seen between these measures.  A 
representative comparison is shown in Figure 5.2.  Gene expression in the 
cDNA of interest was normalised to the expression in the reference cDNA.   
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Figure 5.2 Gene expression measured with microarray in Cy5 labelled sample 
cDNA and Cy3 labelled reference cDNA. 
 
cDNA microarray analysis revealed 223 clones derived from lean-NGT P. 
obesus displayed significantly greater expression in lean-NGT, than obese-
diabetic P. obesus (p<0.05).  5 of these clones were highly significantly 
differentially expressed (p<0.01).  274 clones derived from obese-diabetic P. 
obesus displayed significantly greater expression in obese-diabetic P. obesus 
(p<0.05).  4 of these clones were highly significantly differentially expressed 
(p<0.01).  These 9 clones with the most significant difference in gene 
expression were sequenced (Tables 5.3 and 5.4 respectively).  AGT A5G15 
revealed 87 percent homology to Mus musculus Sulfotransferase Related 
Protein (Genebank no. AF0260752).  AGT C12A15 revealed 86 percent 
homology to Mus musculus Albumin (Genebank no. AJ011413).  7 clones did 
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not show significant evidence of homology with known genes or ESTs on the 
NCBI database (http://www.ncbi.nlm.nih.gov).   
 
Table 5.3 Clones overexpressed in lean-NGT P. obesus.   Homologies with 
known genes and ESTs on NCBI databases, and statistical significance of the 
differential gene expression are shown. 
 
Clone Gene 
Homology 
Genebank 
Accession no. 
Overexpression P 
Value
AGT A1O14 Novel N/A 1.41 0.005 
AGT A9C14 Novel N/A 1.25 0.006 
AGT A9C22 Novel N/A 1.25 0.007 
AGT A10G23 Novel N/A 1.47 0.008 
AGT A5G15 Sulfotransferase 
Related Protein 
AF026075 1.32 0.009 
 
Table 5.4 Clones overexpressed in obese-diabetic P. obesus.   Homologies 
with known genes and ESTs on NCBI databases, and statistical significance of 
the differential gene expression are shown. 
 
Clone Gene 
Homology 
Genebank 
Accession no. 
Overexpression P 
Value
AGT C11L19 Novel N/A 1.38 0.002 
AGT C12A15 Albumin AJ011413 1.77 0.006 
AGT C6P3 Novel N/A 1.41 0.008 
AGT C8D19 Novel N/A 1.28 0.009 
 
5.5 DISCUSSION 
SSH successfully enriched a cDNA library approximately 1000 fold for genes 
differentially expressed between lean-NGT and obese-diabetic P obesus.  8064 
putatively differentially expressed clones were selected for screening with 
cDNA microarray.   
 
SSH and cDNA microarray identified 223 clones overexpressed in lean-NGT 
P. obesus and 274 clones overexpressed in obese-diabetic P. obesus.  9 of the 
differentially expressed clones identified from the microarray screen were 
sequenced.  7 novel genes were identified as well as; sulfotransferase related 
protein and albumin.  Sulfotransferase catalyzes the sulfate conjugation of 
monoamines and phenolic and cathecol drugs (Cooper et al., 2001).  Albumin 
is the main plasma protein and has a good binding capacity for many minerals, 
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fatty acids, hormones and drugs and is involved in the regulation of the 
osmotic pressure of blood (Peters, 1995).  These 2 genes have not previously 
been associated with either type 2 diabetes or obesity.  It is unclear why 
hepatic expression of these genes may differ between lean-NGT and obese-
diabetic groups of P. obesus.   
 
Future studies will utilise SYBR Green PCR to confirm differential expression 
of these genes, similar to the confirmation experiments in Chapter 4.  Hepatic 
gene expression will be measured in the animals used in the microarray 
screening as well as another independent group of lean-NGT, obese-IGT and 
obese-diabetic P. obesus.  Subsequent studies to further elucidate any potential 
role in type 2 diabetes should measure hepatic expression in fed, fasted and 
dieatary energy restricted P. obesus. 
 
Completion of confirmation experiments with SYBR Green PCR will allow 
conclusions to be drawn regarding how closely cDNA microarray correlates 
with expression measured with SYBR Green PCR will allow conclusions to be 
drawn regarding the magnitude of differential expression and the level of 
statistical confidence necessary to confirm genes identified from microarray as 
differentially expressed in the livers of these animals.   
 
The majority of previous studies utilising SSH have been of a relatively small 
scale and have relied on dot blots, northern blots, reverse northern blots, 
cDNA microarray or a combination of these approaches to screen putatively 
differentially expressed genes (von Stein et al., 1997; Kuang et al., 1998; 
Welford et al., 1998; Yang et al., 1999; Corominola et al., 2001; Larose et al., 
2001; Li et al., 2001; Gardmo et al., 2002; Li et al., 2002).  Although the 
accuracy, reproducibility and cost effectiveness of these approaches vary, all 
can be used effectively when only a few hundred clones are to be screened.  
However, the practicality of dot blot and northern blot based approaches can 
become prohibitive when several thousand clones are to be screened.  The 
studies by von stein et al (1997) and Corominola et al (2001) used reverse 
northerns to screen 5000 and 13,800 clones respectively, in what must have 
been time consuming and labour intensive experiments.  The rapid 
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advancement of cDNA microarray technology has ensured this technique is an 
accurate, reproducible and cost effective approach for large scale gene 
expression screening. 
 
Microarray technology is advantageous compared to dot blots and northern 
blots in several aspects.  Firstly, microscope slides can be exposed to two 
cDNA samples labelled with different fluorescent dyes simultaneously, 
allowing competitive hybridisations between the sample of interest and a 
control (Duggan et al., 1999).  Secondly, microscope slides provide an 
impermeable surface, maximizing hybridisation rates and signal intensity 
(Southern et al., 1999).   Thirdly, up to 20,000 clones can be screened 
simultaneously with cDNA microarray (Wildsmith and Elcock, 2001).  
Therefore the current study was able to measure the expression of 8064 genes 
in 20 individual animals.  
 
Given SSH was used to enrich the cDNA library for overexpressed genes, we 
expected many of the 8064 genes to be highly differentially expressed 
between lean-NGT and obese-diabetic groups.  The study by Yang et al 
(1999) utilising SSH and microarray to screen 332 clones putatively 
differentially expressed between two breast cancer cell lines, found 21 genes 
were differentially expressed by more than two fold.  The microarray 
screening in the current study utilised two groups of P. obesus (n=20), a 
heterogenous animal model of a complex polygenic disease, possibly 
explaining why the nine highly significantly differentially expressed genes 
identified in the current study were overexpressed by less than two fold.   
 
Furthermore, the magnitude of differential expression between groups does 
not necessarily relate to the magnitude of the physiological effect.  For some 
tightly controlled metabolic genes a difference in gene expression of less than 
1.5 fold may result in a significant physiological effect, whereas as a 2-3 fold 
difference in other genes may be physiologically ineffectual (Strausberg and 
Riggins, 2001).  Statistical confidence in differential expression in a number 
of animals may be a more important factor in identifying differentially 
expressed genes. 
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cDNA microarray technology can be used as an independent gene discovery 
approach to screen a cDNA library, without the use of SSH.  However, 
incorporating the SSH technique to enrich the cDNA for differential expressed 
genes reduced the total number of clones to be screened and improved the 
efficiency and practicality of the technique.  A large number of clones still 
need to be screened due to the level of redundancy.  As only 12 clones were 
sequenced an accurate estimation of redundancy could not be determined, 
although it is likely to be high given redundancy can be generated in both the 
PCR steps of the SSH procedure as well as during clone selection.   
 
5.5.1 Summary 
In summary SSH enriched a cDNA library for genes differentially expressed 
between lean-NGT and obese-diabetic P. obesus.  cDNA microarray  screened 
8064 clones, identifying 497 differentially expressed clones.  9 clones were 
sequenced revealing sulfotransferase related protein, albumin and 7 novel 
genes.  Future studies will utilise SYBR Green PCR to confirm the differential 
expression of these genes.  Subsequent studies will explore the potential role 
of these genes in the pathophysiology of type 2 diabetes. 
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Conclusions and Future Directions 
 
The physiological data presented in this thesis have further validated 
Psammomys obesus as an ideal animal model of obesity and type 2 diabetes.  
Similar to humans, obesity was accompanied by increased energy expenditure 
and fat oxidation, and type 2 diabetes was not associated with a defect in 
whole body glucose oxidation.  Furthermore, P. obesus responded to dietary 
energy restriction and short term fasting response with energy conservation 
and glucose sparing.  Interestingly, diurnal elevations in blood glucose levels 
and fat oxidation were identified in obese-diabetic animals. The physiological 
significance of these diurnal disturbances in glucose and fat metabolism and 
their potential role in the pathogenesis of obesity and type 2 diabetes should be 
investigated further. 
 
Longitudinal studies with healthy young P. obesus are necessary to identify 
metabolic disturbances causing obesity and diabetes in these animals.  Indirect 
calorimetry should be used to determine whether disproportionately low 
energy expenditure is present in the pre-obese state.  Furthermore, these 
studies should explore any potential disturbances in substrate oxidation that 
may contribute to the pathophysiology of obesity and type 2 diabetes in P. 
obesus.  
 
Previous studies have established the polygenic and heterogeneous nature of 
obesity and type 2 diabetes in P. obesus.  This study has provided additional 
evidence of the similarity between human subjects and P. obesus with respect 
to the pathophysiology of obesity and type 2 diabetes.  These animals are 
therefore ideally suited for studies designed to identify genes involved in the 
pathophysiology of these diseases. 
 
This thesis aimed to identify hepatic genes differentially expressed with the 
presence of obesity and type 2 diabetes in P. obesus.  Suppression subtractive 
hybridisation (SSH) was successfully used to enrich a cDNA library for 
differentially expressed genes.  cDNA dot blots were used to successfully 
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screen several hundred putatively differentially expressed clones (Chapter 4) 
and cDNA microarray was used to screen several thousand clones (Chapter 5).   
 
SSH and cDNA dot blot screening identified thyroxine binding globulin 
(TBG) and site 1 protease (S1P) as genes associated with obesity and diabetes 
in P. obesus.  TBG may be involved in the development of obesity through its 
role in thyroid hormone metabolism.  Future studies should examine the 
relationship between energy metabolism and the concentration of free and 
bound thyroid hormones in the circulation of P. obesus.  Furthermore the 
effect of thyroid hormone administration should be examined utilising indirect 
calorimetry.  To establish a causal role for TBG, gene knockout or antisense 
experiments could be conducted to decrease TBG activity, and transgenic or 
adenoviral studies could increase TBG activity in P. obesus.  Modulation of 
TBG may represent a novel therapeutic approach for the treatment of obesity. 
 
S1P may be involved in the development of obesity and diabetes through its 
role in processing sterol regulating element binding proteins (SREBP), as 
SREBPs are insulin responsive transcription factors involved in lipid 
metabolism.  Future studies should examine the relationship between plasma 
and hepatic lipid levels with the hepatic expression and activity levels of 
SREBP isoforms (1a, 1c, 2) as well as SREBP regulators (S1P, site 2 protease 
and SREBP cleavage activating protein).  To establish a causal role for S1P, 
studies should be conducted to modulate the activity of this enzyme.  Gene 
knockout or antisense experiments could be conducted to decrease S1P 
activity, and transgenic or adenoviral studies could increase S1P activity in P. 
obesus.  Modulating S1P mediated SREBP activity may potentially represent a 
new therapeutic approach to improve blood lipid and glucose profiles. 
 
SSH and a cDNA microarray screening identified 223 clones overexpressed in 
lean-NGT P. obesus and 274 clones overexpressed in obese-diabetic P. 
obesus.  Sequencing the 9 clones with the most highly significant differential 
expression identified 7 novel genes as well as sulfotransferase related protein 
and albumin.  These 2 genes have not previously been associated with either 
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type 2 diabetes or obesity.  It is unclear why hepatic expression of these genes 
may differ between lean-NGT and obese-diabetic groups of P. obesus.   
 
Time constraints prevented the studies necessary to confirm the differential 
gene expression of these 9 genes.  SYBR Green PCR should be used to firstly 
confirm the gene expression in the 20 animals used in the microarray screen 
followed by another group of lean-NGT, obese-IGT and obese-diabetic P. 
obesus.  Subsequent studies to explore any potential role of these genes in type 
2 diabetes and metabolism should measure hepatic gene expression in fed, 
fasted and dietary energy restricted P. obesus.  Genes identified from these 
gene expression studies as potentially involved in the pathophysiology of type 
2 diabetes could be examined further using in vitro or in vivo studies to 
modulate gene activity with either gene knockout, antisense, transgenic or 
adenoviral studies, to establish any casual role in the pathophysioloogy of type 
2 diabetes.     
 
The two SSH experiments conducted have demonstrated the effectiveness of 
the technique to enrich a cDNA library for differentially expressed genes.  Dot 
blots and microarrays were both used effectively to screen cDNA libraries.  
Microarray technology was advantageous to dot blots in two main areas; 
firstly expression levels were measured in thousands of genes in a single 
experiment, and secondly experiments were conducted with 20 individual liver 
cDNA samples, thereby avoiding the need to pool samples together.  Although 
cDNA microarray technology could be used as an independent gene discovery 
approach to screen a cDNA library, incorporating the SSH technique enriched 
the cDNA for differential expressed genes and reduced the total number of 
clones to be screened.  Therefore the combination of SSH and cDNA 
microarray techniques maximises the efficiency and practicality of the 
individual techniques and can be a powerful gene discovery strategy.   
 
Future gene discovery studies should continue to focus on the liver, given the 
role of the liver in both glucose and fat metabolism and the established role in 
the pathophysiology of type 2 diabetes.  However, other tissues with metabolic 
defects contributing to diabetes including skeletal muscle, pancreas and 
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adipose tissue, particularly visceral adipose tissue should also be examined.  
Identification of genetic defects contributing to the pathogenesis of type 2 
diabetes will hopefully lead to new and improved therapeutic approaches. 
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